10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001193125-19-034030.txt : 20190211 0001193125-19-034030.hdr.sgml : 20190211 20190211162959 ACCESSION NUMBER: 0001193125-19-034030 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190211 DATE AS OF CHANGE: 20190211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERIDIAN BIOSCIENCE INC CENTRAL INDEX KEY: 0000794172 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 310888197 STATE OF INCORPORATION: OH FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-14902 FILM NUMBER: 19585879 BUSINESS ADDRESS: STREET 1: 3471 RIVER HILLS DR CITY: CINCINNATI STATE: OH ZIP: 45244 BUSINESS PHONE: 5132713700 MAIL ADDRESS: STREET 1: 3471 RIVER HILLS DRIVE CITY: CINCINNATI STATE: OH ZIP: 45244 FORMER COMPANY: FORMER CONFORMED NAME: MERIDIAN DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 10-Q 1 d627978d10q.htm 10-Q 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended December 31, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-14902

MERIDIAN BIOSCIENCE, INC.

Incorporated under the laws of Ohio

31-0888197

(I.R.S. Employer Identification No.)

3471 River Hills Drive

Cincinnati, Ohio 45244

(513) 271-3700

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


Class		Outstanding January 31, 2019
Common Stock, no par value		42,489,202

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

TABLE OF CONTENTS TO QUARTERLY REPORT ON FORM 10-Q


		Page(s)
PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Statements of Operations Three Months Ended December 31, 2018 and 2017		1
	Condensed Consolidated Statements of Comprehensive Income Three Months Ended December 31, 2018 and 2017		2

	Condensed Consolidated Statements of Cash Flows Three Months Ended December 31, 2018 and 2017		3

	Condensed Consolidated Balance Sheets December 31, 2018 and September 30, 2018		4-5

	Condensed Consolidated Statements of Changes in Shareholders’ Equity Three Months Ended December 31, 2018 and 2017		6

	Notes to Condensed Consolidated Financial Statements		7-15

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15-22

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		23

Item 4.	Controls and Procedures		23

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings		23

Item 1A.	Risk Factors		23

Item 6.	Exhibits		23

Signature			24

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian’s forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s operating results, financial condition and continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, its ability to effectively sell such products and its ability to successfully expand and effectively manage increased sales and marketing operations. While Meridian has introduced a number of internally developed products and acquired products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis or in protecting its intellectual property, and unexpected or costly manufacturing costs associated with its introduction of new products or acquired products could cause actual results to differ from expectations. Meridian relies on proprietary, patented and licensed technologies. As such, the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products, as can the uncertainty of regulatory approvals and the regulatory process. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention, and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the outcome of goodwill impairment testing and the impact of possible goodwill impairments on Meridian’s earnings and financial results. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof initiated by Congress or the presidential administration, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian’s information technology systems, trade wars, increased tariffs, and natural disasters and other events could have a materially adverse effect on Meridian’s results of operations and revenues. In the past, the Company has identified a material weakness in our internal control over financial reporting, which has been remediated, but the Company can make no assurances that a material weakness will not be identified in the future, which if identified and not properly corrected, could materially adversely affect our operations and result in material misstatements in our financial statements. In addition to the factors described in this paragraph, as well as those factors identified from time to time in our filings with the Securities and Exchange Commission, Part I, Item 1A Risk Factors of our most recent Annual Report on Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company. Readers should carefully review these forward-looking statements and risk factors, and not place undue reliance on our forward-looking statements.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)


	Three Months Ended
	December 31,
	2018			2017
NET REVENUES	$	51,480		$	52,283
COST OF SALES		19,908			20,273

GROSS PROFIT		31,572			32,010

OPERATING EXPENSES
Research and development		3,967			4,420
Selling and marketing		7,563			8,844
General and administrative		8,902			9,202
Restructuring costs		—			734
Litigation costs		589			749

Total operating expenses		21,021			23,949

OPERATING INCOME		10,551			8,061
OTHER INCOME (EXPENSE)
Interest income		149			72
Interest expense		(363	)		(395	)
Other, net		139			(80	)

Total other expense		(75	)		(403	)

EARNINGS BEFORE INCOME TAXES		10,476			7,658
INCOME TAX PROVISION		2,370			1,356

NET EARNINGS	$	8,106		$	6,302

BASIC EARNINGS PER COMMON SHARE	$	0.19		$	0.15
DILUTED EARNINGS PER COMMON SHARE	$	0.19		$	0.15
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC		42,446			42,263
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARE UNITS		459			399

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED		42,905			42,662

ANTI-DILUTIVE SECURITIES:
Common share options and restricted share units		684			1,034

DIVIDENDS DECLARED PER COMMON SHARE	$	0.125		$	0.125

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 1

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(dollar amounts in thousands)


	Three Months Ended
	December 31,
	2018			2017
NET EARNINGS	$	8,106		$	6,302
Other comprehensive income (loss):
Foreign currency translation adjustment		(716	)		291
Unrealized gain (loss) on cash flow hedge		(577	)		341
Income taxes related to items of other comprehensive income		145			(112	)

Other comprehensive income (loss), net of tax		(1,148	)		520

COMPREHENSIVE INCOME	$	6,958		$	6,822

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 2

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(dollar amounts in thousands)


Three Months Ended December 31,	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	8,106		$	6,302
Non-cash items included in net earnings:
Depreciation of property, plant and equipment		1,253			1,146
Amortization of intangible assets		829			938
Amortization of deferred instrument costs		—			201
Stock-based compensation		1,670			1,759
Deferred income taxes		96			(1,624	)
Change in:
Accounts receivable		317			(2,989	)
Inventories		(37	)		(2,353	)
Prepaid expenses and other current assets		539			87
Accounts payable and accrued expenses		(4,081	)		1,315
Income taxes payable		991			497
Other, net		(276	)		(108	)

Net cash provided by operating activities		9,407			5,171

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(1,109	)		(1,234	)

Net cash used for investing activities		(1,109	)		(1,234	)

CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid		(5,301	)		(5,288	)
Payments on term loan		(1,125	)		(1,125	)
Proceeds and tax benefits from exercises of stock options		145			—

Net cash used for financing activities		(6,281	)		(6,413	)

Effect of Exchange Rate Changes on Cash and Equivalents and Restricted Cash		(257	)		115

Net Increase (Decrease) in Cash and Equivalents and Restricted Cash		1,760			(2,361	)
Cash and Equivalents and Restricted Cash at Beginning of Period		60,763			58,072

Cash and Equivalents and Restricted Cash at End of Period	$	62,523		$	55,711


Cash and Equivalents	$	61,523		$	54,711
Restricted Cash		1,000			1,000

Cash and Equivalents and Restricted Cash at End of Period	$	62,523		$	55,711

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 3

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(dollar amounts in thousands)

ASSETS


	December 31, 2018 (Unaudited)		September 30, 2018
CURRENT ASSETS
Cash and equivalents	$	61,523	$	59,763
Accounts receivable, less allowances of $331 and $310		31,791		32,336
Inventories		41,889		41,993
Prepaid expenses and other current assets		4,411		4,961

Total current assets		139,614		139,053

PROPERTY, PLANT AND EQUIPMENT, at Cost
Land		1,158		1,160
Buildings and improvements		32,443		32,444
Machinery, equipment and furniture		59,637		50,606
Construction in progress		1,727		1,631

Subtotal		94,965		85,841
Less: accumulated depreciation and amortization		64,108		55,846

Net property, plant and equipment		30,857		29,995

OTHER ASSETS
Goodwill		54,403		54,637
Other intangible assets, net		22,265		23,113
Restricted cash		1,000		1,000
Deferred instrument costs, net		—		1,239
Fair value of interest rate swap		1,145		1,722
Deferred income taxes		121		130
Other assets		452		488

Total other assets		79,386		82,329

TOTAL ASSETS	$	249,857	$	251,377

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 4

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(dollar amounts in thousands)

LIABILITIES AND SHAREHOLDERS’ EQUITY


	December 31, 2018 (Unaudited)			September 30, 2018
CURRENT LIABILITIES
Accounts payable	$	6,228		$	6,260
Accrued employee compensation costs		4,779			7,263
Other accrued expenses		3,035			5,065
Current portion of long-term debt		5,625			5,250
Income taxes payable		1,023			335

Total current liabilities		20,690			24,173

NON-CURRENT LIABILITIES
Post-employment benefits		2,490			2,646
Long-term debt		43,438			44,930
Long-term income taxes payable		736			441
Deferred income taxes		3,861			3,769

Total non-current liabilities		50,525			51,786

COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY
Preferred stock, no par value; 1,000,000 shares authorized; none issued		—			—
Common shares, no par value; 71,000,000 shares authorized, 42,488,602 and 42,399,962 shares issued, respectively		—			—
Additional paid-in capital		130,876			129,193
Retained earnings		52,291			49,602
Accumulated other comprehensive loss		(4,525	)		(3,377	)

Total shareholders’ equity		178,642			175,418

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	249,857		$	251,377

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 5

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited)

(dollar and share amounts in thousands, except per share data)


	Common Shares Issued		Additional Paid-In Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Total Shareholders’ Equity
Balance at September 30, 2018		42,400	$	129,193	$	49,602		$	(3,377	)	$	175,418
Cash dividends paid - $0.125 per share		—		—		(5,301	)		—			(5,301	)
Conversion of restricted share units and exercise of stock options		89		13		—			—			13
Stock compensation expense		—		1,670		—			—			1,670
Net earnings		—		—		8,106			—			8,106
Foreign currency translation adjustment		—		—		—			(716	)		(716	)
Hedging activity, net of tax		—		—		—			(432	)		(432	)
Adoption of ASU 2014-09		—		—		(116	)		—			(116	)

Balance at December 31, 2018		42,489	$	130,876	$	52,291		$	(4,525	)	$	178,642

Balance at September 30, 2017		42,207	$	125,608	$	46,923		$	(2,946	)	$	169,585
Cash dividends paid - $0.125 per share		—		—		(5,288	)		—			(5,288	)
Conversion of restricted share units		100		—		—			—			—
Stock compensation expense		—		1,759		—			—			1,759
Net earnings		—		—		6,302			—			6,302
Foreign currency translation adjustment		—		—		—			291			291
Hedging activity, net of tax		—		—		—			229			229

Balance at December 31, 2017		42,307	$	127,367	$	47,937		$	(2,426	)	$	172,878

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 6

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Dollars in Thousands, Except Per Share Amounts

(Unaudited)

1.	Basis of Presentation

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of December 31, 2018, the results of its operations for the three month periods ended December 31, 2018 and 2017, and its cash flows for the three month periods ended December 31, 2018 and 2017. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s fiscal 2018 Annual Report on Form 10-K. Financial information as of September 30, 2018 has been derived from the Company’s audited consolidated financial statements. The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

2.	Significant Accounting Policies

A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 2018 Annual Report on Form 10-K and should be referred to for a description of the Company’s current significant accounting policies, with the exception of Revenue Recognition, which is set forth below.

Revenue Recognition –

Adoption of New Standard

On October 1, 2018, we adopted ASU No. 2014-09, Revenue from Contracts with Customers, using the modified retrospective transition method applied to those contracts that were not completed as of that date. Results for reporting periods beginning on or after October 1, 2018 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previously applicable guidance.

Upon adoption, we recorded a reduction of $116 to the opening balance of retained earnings as of October 1, 2018. This adjustment is related to writing off the book value of clinical diagnostic testing instruments located at customers for which there is no contractual arrangement for the instrument to be returned to the Company. Instruments placed with customers under an agreement to return the instrument to the Company were reclassified to machinery and equipment. Prior to adoption of the new guidance, all instruments placed with customers were capitalized and amortized over an estimated three-year utilization period, with the net balance reflected as deferred instrument costs.

Page 7

The following table summarizes the impact of the new revenue standard on our opening balance sheet:


	Balance at September 30, 2018			New Revenue Standard Adjustment			Balance at October 1, 2018
PROPERTY, PLAN AND EQUIPMENT
Machinery, equipment and furniture	$	50,606		$	8,696		$	59,302
Accumulated depreciation and amortization		(55,846	)		(7,611	)		(63,457	)
OTHER ASSETS
Deferred instrument costs, net		1,239			(1,239	)		—
NON-CURRENT LIABILITIES
Deferred income taxes		(3,769	)		38			(3,731	)
SHAREHOLDERS’ EQUITY
Retained earnings		(49,602	)		116			(49,486	)

The adoption of this new standard had an immaterial impact on our reported total revenues and operating income, as compared to what would have been reported under the prior standard. We expect the impact of adoption in future periods to continue to be immaterial. Our accounting policies under the new standard were applied prospectively and are noted below following the discussion of Revenue Disaggregation.

Revenue Disaggregation

The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only):

Revenue by Reportable Segment & Geographic Region


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Americas	$	31,147	$	31,575		(1	)%
EMEA		5,085		5,415		(6	)%
ROW		433		500		(13	)%

Total Diagnostics		36,665		37,490		(2	)%

Life Science-
Americas		4,534		5,250		(14	)%
EMEA		7,455		5,185		44	%
ROW		2,826		4,358		(35	)%

Total Life Science		14,815		14,793		—	%

Consolidated	$	51,480	$	52,283		(2	)%

Page 8

Revenue by Product Platform/Type


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Molecular assays	$	7,298	$	8,717		(16	)%
Immunoassays & blood chemistry assays		29,367		28,773		2	%

Total Diagnostics	$	36,665	$	37,490		(2	)%

Life Science-
Molecular reagents	$	6,589	$	5,688		16	%
Immunological reagents		8,226		9,105		(10	)%

Total Life Science	$	14,815	$	14,793		—	%

Revenue by Disease State (Diagnostics only)


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Gastrointestinal assays	$	18,633	$	20,270		(8	)%
Respiratory illness assays		7,977		7,486		7	%
Blood chemistry assays		4,466		4,266		5	%
Other		5,589		5,468		2	%

Total Diagnostics	$	36,665	$	37,490		(2	)%

Revenue Policies

Product Sales

Revenue from contracts with customers is recognized in an amount that reflects the consideration we expect to receive in exchange for products when obligations under such contracts are satisfied. Revenue is generally recognized at a point-in-time when products are shipped and title has passed to the customer. Such contracts can include various combinations of products that are generally accounted for as distinct performance obligations.

Revenue is reduced in the period of sale for fees paid to distributors, which are inseparable from the distributor’s purchase of our product and for which we receive no goods or services in return. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments due to certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals are netted against accounts receivable.

Shipping and handling costs incurred after control of the product is transferred to our customers are treated as fulfillment costs and not a separate performance obligation.

Our payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 90 days from the date of shipment or satisfaction of the performance obligation. Trade accounts receivable are recorded in the accompanying Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience and known conditions that would likely lead to non-payment. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid.

Page 9

Practical Expedients and Exemptions

Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable.

We expense as incurred the costs to obtain contracts, as the amortization period would have been one year or less. These costs, recorded within selling and marketing expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.

Reagent Rental Arrangements

Our Alethia and LeadCare product platforms require the use of instruments for the tests to be processed. In many cases a customer is given use of the instrument, provided they continue purchasing the associated tests, also referred to as “consumables” or “reagents”. If a customer stops purchasing the consumables, the instrument must be returned to Meridian. Such arrangements are common practice in the diagnostics industry and are referred to as “Reagent Rental” agreements. These agreements may also include instrument related services such as a limited replacement warranty, training and installation. We concluded that the use of the instrument and related services (collectively known as “lease elements”) are not within the scope of ASU No. 2014-09 but rather ASU 2016-02, Leases. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on estimates of relative standalone selling prices. Lease revenue is derived solely from the sale of consumables and is therefore recognized monthly as earned, which coincides with the transfer of control of the non-lease elements.

For the portion of the transaction price allocated to the non-lease elements, which are principally the test kits, the related revenue will be recognized at a point-in-time when control transfers.

Revenue allocated to the lease elements of these Reagent Rental arrangements represent less than 1% of total revenue and are included as part of net revenues in our Condensed Consolidated Statements of Income.

Recent Accounting Pronouncements –

In February 2016, the FASB issued ASU 2016-02, Leases, which amends the accounting guidance related to leases. These changes, which are designed to increase transparency and comparability among organizations for both lessees and lessors, include, among other things, requiring recognition of lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2020, although early adoption is permitted. The Company expects to begin its assessment of the impact that adoption of this guidance will have on its financial statements during the second quarter of fiscal 2019.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. The update addresses certain specific cash flows and their treatment, with the objective being to reduce the existing diversity in how the items are presented and classified within the statement of cash flows. The Company adopted this guidance in the first quarter of fiscal 2019, with the Condensed Consolidated Statements of Cash Flows reflecting such adoption, including the information related to restricted cash.

In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, to address certain of the recent U.S. federal income tax legislation’s impact on Accumulated Other Comprehensive Income (“AOCI”). The guidance specifically provides the option of reclassifying “stranded tax effects” related to the tax legislation from AOCI to retained earnings. Adoption and implementation of the optional guidance is not effective for the Company until the beginning of fiscal 2020, although early adoption is permitted. The Company plans to adopt this guidance in fiscal 2020 as required but does not expect adoption to have a significant impact on the Company’s consolidated results of operations, cash flows or financial position.

Page 10

Reclassifications –

Certain reclassifications have been made to the prior year financial statements to conform to the current year presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

3.	Cash and Equivalents

Cash and equivalents include the following components:


	December 31, 2018				September 30, 2018
	Cash and Equivalents		Other Assets		Cash and Equivalents		Other Assets
Institutional money market funds	$	20,540	$	—	$	20,421	$	—
Cash on hand -
Restricted		—		1,000		—		1,000
Unrestricted		40,983		—		39,342		—

Total	$	61,523	$	1,000	$	59,763	$	1,000

4.	Inventories

Inventories are comprised of the following:


	December 31, 2018		September 30, 2018
Raw materials	$	7,123	$	6,689
Work-in-process		12,037		12,098
Finished goods - instruments		1,224		1,191
Finished goods - kits and reagents		21,505		22,015

Total	$	41,889	$	41,993

5.	Intangible Assets

A summary of our acquired intangible assets subject to amortization, as of December 31, 2018 and September 30, 2018, is as follows:


	December 31, 2018				September 30, 2018
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	22,268	$	14,243	$	22,297	$	13,974
Trade names, licenses and patents		8,613		5,463		8,647		5,267
Customer lists, customer relationships and supply agreements		24,385		13,295		24,461		13,051
Non-compete agreements		720		720		720		720

Total	$	55,986	$	33,721	$	56,125	$	33,012

Page 11

The actual aggregate amortization expense for these intangible assets was $829 and $938 for the three months ended December 31, 2018 and 2017, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2024 is as follows: remainder of fiscal 2019 – $2,487, fiscal 2020 – $3,156, fiscal 2021 – $2,560, fiscal 2022 – $2,182, fiscal 2023 – $2,170, and fiscal 2024 – $2,166.

6.	Restructuring

During the second quarter of fiscal 2018, the Company began implementation of a plan to realign its business structure into two business units, Diagnostics and Life Science, supported by a global corporate team. As part of this plan, certain functions and locations within both business units were streamlined, including: (i) the elimination of certain executive management and commercial sales positions; (ii) the closing of Life Science locations in Taunton, Massachusetts and Singapore, the operations of which were transferred to locations in Memphis, Tennessee and London, England, respectively; and (iii) the transfer of certain functions performed in the Billerica, Massachusetts Diagnostics facility to the corporate headquarters in Cincinnati, Ohio. As a result of these activities, restructuring costs totaling $6,332 were recorded during the fiscal year ended September 30, 2018.

A summary of the accrued liability associated with the restructuring costs as of December 31, 2018 and September 30, 2018, is as follows:


	December 31, 2018		September 30, 2018
Severance, other termination benefits and related costs	$	368	$	987
Lease and other contract termination fees		8		33
Other		5		6

Total	$	381	$	1,026

7.	Income Taxes

On December 22, 2017, the United States enacted tax reform legislation commonly known as the Tax Cuts and Jobs Act (the “tax reform act”). In applying the tax reform act during the three months ended December 31, 2017, we followed the guidance in SEC Staff Accounting Bulletin 118 (“SAB 118”), regarding the application of ASC Topic 740 in situations where a company does not have the necessary information available, prepared or analyzed in reasonable detail to complete the accounting for certain income tax effects of the tax reform act for the reporting period in which the tax reform act was enacted. SAB 118 provides for a measurement period beginning in the reporting period that includes the tax reform act’s enactment date and ending when a company has obtained, prepared and analyzed the information needed in order to complete the accounting requirements, but in no circumstances should the measurement period extend beyond one year from the enactment date.

As a result, our financial statements for the three months ended December 31, 2017 reflected the effects of the tax reform act as provisional based on a reasonable estimate of the income tax effects and included a provisional noncurrent income tax payable in the amount of $854 related to the repatriation transition tax. Subsequent to the quarter ended December 31, 2017 and prior to September 30, 2018, we completed the accounting for the effects of the tax reform act. As a result, our repatriation transition tax liability was increased to $876, which is reflected as follows in the accompanying Condensed Consolidated Balance as of December 31, 2018: $140 of current income taxes payable and $736 long-term income taxes payable.

In addition, during the three months ended December 31, 2017 we recorded a one-time tax benefit of $1,695 resulting from the tax reform act, including an adjustment from the re-measurement of deferred tax assets and liabilities. This re-measurement included an estimate of the temporary differences expected to be realized during fiscal 2018 at a transitional blended rate of 24.5%. The remaining temporary differences were re-measured at 21%.

Page 12

8.	Bank Credit Arrangements

In March 2016, the Company entered into a $60,000 five-year term loan with a commercial bank. The term loan requires quarterly principal and interest payments, with interest at a variable rate tied to LIBOR, and a balloon principal payment due March 31, 2021. The required principal payments on the term loan for each of the remaining fiscal years are as follows: remainder of fiscal 2019 – $4,125, fiscal 2020 – $6,000, and fiscal 2021 – $39,000. In light of the term loan’s interest being determined on a variable rate basis, the fair value of the term loan at December 31, 2018 approximates the current carrying value reflected in the accompanying Condensed Consolidated Balance Sheet.

In order to limit exposure to volatility in the LIBOR interest rate, the Company and the commercial bank also entered into an interest rate swap that effectively converts the variable interest rate on the term loan to a fixed rate of 2.76%. With an initial notional balance of $60,000, the interest rate swap was established with critical terms identical to those of the term loan, including: (i) notional reduction amounts and dates; (ii) LIBOR settlement rates; (iii) rate reset dates; and (iv) term/maturity. Due to this, the interest rate swap has been designated as an effective cash flow hedge, with changes in fair value reflected as a separate component of other comprehensive income in the accompanying Condensed Consolidated Statements of Comprehensive Income. At December 31, 2018 and September 30, 2018, the fair value of the interest rate swap was $1,145 and $1,722, respectively, and is reflected as a non-current asset in the accompanying Condensed Consolidated Balance Sheets. This fair value was determined by information provided by the counterparty, and is considered a Level 2 input within the fair value hierarchy of valuation techniques.

In addition, the Company maintains a $30,000 revolving credit facility with a commercial bank, which expires March 31, 2021. There were no borrowings outstanding on this credit facility at December 31, 2018 or September 30, 2018.

The term loan and the revolving credit facility are collateralized by the business assets of the Company’s U.S. subsidiaries and require compliance with financial covenants that limit the amount of debt obligations and require a minimum level of coverage of fixed charges, as defined in the borrowing agreement. As of December 31, 2018, the Company is in compliance with all covenants. The Company is also required to maintain a compensating cash balance with the bank in the amount of $1,000, and is in compliance with this requirement.

9.	Reportable Segment and Major Customers Information

Meridian was formed in 1976 and functions as a fully-integrated life science company with principal businesses in: (i) the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers and other diagnostic manufacturers.

Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio, and manufacturing operations for blood chemistry products in Billerica, Massachusetts (near Boston), and the sale and distribution of diagnostics products domestically and abroad. This segment’s products are used by hospitals, reference labs and physician offices to detect infectious diseases and elevated lead levels in blood.

The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents domestically and abroad, including a sales and business development facility in Beijing, China to further pursue growing revenue opportunities in Asia. This segment’s products are used by manufacturers and researchers in a variety of applications (e.g., in-vitro medical device manufacturing, microRNA detection, next-gen sequencing, plant genotyping, and mutation detection, among others).

Page 13

Amounts due from two Diagnostics distributor customers accounted for 14% and 12% of consolidated accounts receivable at December 31, 2018 and September 30, 2018, respectively. Revenues from these two distributor customers accounted for 34% and 32% of the Diagnostics segment third-party revenues during the three months ended December 31, 2018 and 2017, respectively, and represented 24% and 23% of consolidated revenues for the fiscal 2019 and 2018 first quarters, respectively.

Within our Life Science segment, two diagnostic manufacturing customers accounted for 28% and 15% of the segment’s third-party revenues during the three months ended December 31, 2018 and 2017, respectively.

Segment information for the interim periods is as follows:


	Diagnostics		Life Science		Corporate⁽¹⁾			Eliminations⁽²⁾			Total
Three Months Ended December 31, 2018
Net revenues -
Third-Party	$	36,665	$	14,815	$	—		$	—		$	51,480
Inter-segment		163		176		—			(339	)		—
Operating income		8,786		5,129		(3,391	)		27			10,551
Goodwill (December 31, 2018)		35,213		19,190		—			—			54,403
Other intangible assets, net (December 31, 2018)		21,386		879		—			—			22,265
Total assets (December 31, 2018)		178,863		71,283		—			(289	)		249,857
Three Months Ended December 31, 2017
Net revenues -
Third-Party	$	37,490	$	14,793	$	—		$	—		$	52,283
Inter-segment		121		192		—			(313	)		—
Operating income		8,569		2,943		(3,555	)		104			8,061
Goodwill (September 30, 2018)		35,213		19,424		—			—			54,637
Other intangible assets, net (September 30, 2018)		22,068		1,045		—			—			23,113
Total assets (September 30, 2018)		180,978		70,341		—			58			251,377

(1)	Includes Restructuring and Litigation Costs of $589 and $1,483 in the quarters ended December 31, 2018 and 2017, respectively.

(2)	Eliminations consist of inter-segment transactions.

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

10.

Litigation Matters

On November 15, 2017, Barbara Forman filed a class action complaint in the United States District Court for the Southern District of Ohio naming Meridian, its Chief Executive Officer and Chief Financial Officer (in their capacities as such) as defendants. An amended complaint was filed on April 16, 2018 and the Company believes the essential elements of the amended complaint are the same. The complaint and the amended complaint are hereafter referred to as the “Complaint”. The Complaint seeks compensatory damages and attorneys’ fees. Meridian has filed a motion to dismiss the Complaint, to which the plaintiff responded on August 14, 2018. The motion has been fully briefed and remains pending before the court. We are unable to determine or predict the ultimate outcome or estimate the range of possible losses, if any. Accordingly, no provision for litigation losses has been included within either of the accompanying Condensed Consolidated Statements of Operations for the three months ended December 31, 2018 or December 31, 2017.

Page 14

On December 6, 2017, Michael Edelson filed a derivative complaint in the United States District Court for the Southern District of Ohio naming Meridian, its Chief Executive Officer, Chief Financial Officer and certain members of Meridian’s Board of Directors and Audit Committee (in their capacities as such) as defendants. The complaint alleges that Meridian made false and misleading representations concerning certain of Magellan’s lead test systems at or around the time of Meridian’s acquisition of Magellan and subsequent thereto, and the complaint alleges that certain members of the Board of Directors and Audit Committee breached their fiduciary duties in their oversight of the Company’s public disclosures and corporate governance matters. The complaint seeks compensatory damages, equitable relief relating to corporate governance matters and attorneys’ fees. The case has been stayed by agreement of the parties pending resolution of the motion to dismiss the class action described above. We are unable to determine or predict the ultimate outcome or estimate the range of possible losses, if any. Accordingly, no provision for litigation losses has been included within either of the accompanying Condensed Consolidated Statements of Operations for the three months ended December 31, 2018 or December 31, 2017. The Company maintains an insurance policy covering these matters, which has a $500 deductible.

On April 17, 2018, Magellan received a subpoena from the United States Department of Justice (“DOJ”) regarding its LeadCare product line. The subpoena outlines documents to be produced, and the Company is cooperating with the DOJ in this matter. The Company maintains rigorous policies and procedures to promote compliance with applicable regulatory agencies and requirements, and is working with the DOJ to promptly respond to the subpoena. However, the Company cannot predict when the investigation will be resolved, the outcome of the investigation, or its potential impact on the Company. Approximately $540 and $0 of expense for attorneys’ fees related to this matter is included within the accompanying Condensed Consolidated Statements of Operations for the three months ended December 31, 2018 and December 31, 2017, respectively.

On October 9, 2018, the Company and DiaSorin Inc. entered into a strategic collaboration to sell DiaSorin’s Helicobacter pylori stool antigen test to detect H. pylori for use on its automated LIAISON platform under the Meridian brand name worldwide. The new collaboration results in the termination of all pending legal disputes between the two parties and will expand the previous agreement between DiaSorin and Meridian, which focused on the sale, by DiaSorin, of co-developed products in major countries in continental Europe. Approximately $50 and $730 of expense for attorneys’ fees related to this matter is included within the accompanying Condensed Consolidated Statements of Operations for the three months ended December 31, 2018 and December 31, 2017, respectively.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Refer to “Forward-Looking Statements” following the Table of Contents in front of this Form 10-Q. In the discussion that follows, all dollar amounts are in thousands (both tables and text), except per share data.

Following is a discussion and analysis of the financial statements and other statistical data that management believes will enhance the understanding of Meridian’s financial condition, changes in financial condition and results of operations. This discussion should be read in conjunction with the financial statements and notes thereto beginning on page 1.

Page 15

RESULTS OF OPERATIONS

Three Months Ended December 31, 2018

Net earnings for the first quarter of fiscal 2019 increased 29% to $8,106, or $0.19 per diluted share, from net earnings for the first quarter of fiscal 2018 of $6,302, or $0.15 per diluted share. The fiscal 2019 first quarter results include $589 of litigation costs, while the fiscal 2018 first quarter results include $1,483 of restructuring and litigation costs, along with certain one-time tax effects of the U.S. tax reform act enacted in December 2017. These items had a combined impact on net earnings of $452, or $0.01 per diluted share, in the fiscal 2019 quarter and $239, or less than $0.01 per diluted share, in the fiscal 2018 quarter (see “USE OF NON-GAAP MEASURES” below). Consolidated revenues for the first quarter of fiscal 2019 totaled $51,480, a decrease of 2% compared to the first quarter of fiscal 2018 (1% decrease on a constant-currency basis).

Revenues for the Diagnostics segment for the first quarter of fiscal 2019 decreased 2% compared to the first quarter of fiscal 2018 (also 2% on a constant-currency basis), comprised of a 16% decrease in molecular assay products and a 2% increase in immunoassay and blood chemistry assay products. With a 16% increase in its molecular reagents products and a 10% decrease in its immunological reagents products, revenues for our Life Science segment were flat during the first quarter of fiscal 2019 compared to the first quarter of fiscal 2018. On a constant-currency basis, revenues for the Life Science segment increased 1%.

The first quarter Diagnostics revenues reflect improvement in our respiratory illness and blood chemistry assay product lines being more than offset by decreased revenues for our gastrointestinal assays. Life Science revenues reflect inconsistent buying patterns with a number of our multi-national IVD manufacturing customers and general market softness in North America and China.

USE OF NON-GAAP MEASURES

We have supplemented our reported GAAP financial information with information on operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share excluding the effects of: (i) restructuring costs (fiscal 2018); (ii) litigation costs (fiscal 2019 and 2018); and (iii) certain one-time tax effects of the tax reform act (fiscal 2018) – each of which is a non-GAAP measure. We have provided in the tables below reconciliations to the operating expenses, operating income, net earnings, basic earnings per share and diluted earnings per share amounts reported under U.S. Generally Accepted Accounting Principles. We believe that this information is useful to those who read our financial statements and evaluate our operating results because:

These measures help to appropriately evaluate and compare the results of operations from period to period by removing the impacts of these non-routine items; and

These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.

Revenue reported on a constant-currency basis is also a non-GAAP measure and is calculated by applying current period average foreign currency exchange rates to each of the prior comparable periods. Management analyzes revenue on a constant-currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, management believes that evaluating revenue changes on a constant-currency basis provides an additional and meaningful assessment of revenue to both management and investors.

These non-GAAP measures may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations, in that they do not reflect all amounts associated with our results as determined in accordance with U.S. GAAP. Therefore, these measures should only be used to evaluate our results in conjunction with corresponding GAAP measures.

Page 16


	Three Months
	Ended December 31,
	2018			2017
Operating Expenses -
U.S. GAAP basis	$	21,021		$	23,949
Restructuring costs		—			(734	)
Litigation costs		(589	)		(749	)

Adjusted Operating Expenses	$	20,432		$	22,466

Operating Income -
U.S. GAAP basis	$	10,551		$	8,061
Restructuring costs		—			734
Litigation costs		589			749

Adjusted Operating Income	$	11,140		$	9,544

Net Earnings -
U.S. GAAP basis	$	8,106		$	6,302
Restructuring costs ⁽¹⁾		—			535
Litigation costs ⁽¹⁾		452			545
One-time benefit from tax law change		—			(1,695	)
Repatriation transition tax		—			854

Adjusted Net Earnings	$	8,558		$	6,541

Net Earnings per Basic Common Share -
U.S. GAAP basis	$	0.19		$	0.15
Restructuring costs ⁽¹⁾		—			0.01
Litigation costs ⁽¹⁾		0.01			0.01
One-time benefit from tax law change		—			(0.04	)
Repatriation transition tax		—			0.02

Adjusted Basic EPS	$	0.20		$	0.15

Net Earnings per Diluted Common Share -
U.S. GAAP basis	$	0.19		$	0.15
Restructuring costs ⁽¹⁾		—			0.01
Litigation costs ⁽¹⁾		0.01			0.01
One-time benefit from tax law change		—			(0.04	)
Repatriation transition tax		—			0.02

Adjusted Diluted EPS	$	0.20		$	0.15

(1)	These restructuring costs and litigation costs are net of income tax effects of $137 and $403 in the three months ended December 31, 2018 and 2017, respectively, which were calculated using the effective tax rates of the jurisdictions in which the costs were incurred.

Page 17

REVENUE OVERVIEW

Below are analyses of the Company’s revenue, provided for each of the following:

•

By Reportable Segment & Geographic Region

•

By Product Platform/Type

Revenue Overview- By Reportable Segment & Geographic Region

Our reportable segments are Diagnostics and Life Science, with products sold and distributed in the countries comprising North and Latin America (the “Americas”); Europe, Middle East and Africa (“EMEA”); and other countries outside of the Americas and EMEA (rest of the world, or “ROW”). A full description of our segments is set forth in Note 9 of the accompanying Condensed Consolidated Financial Statements.

Revenues for the Diagnostics segment, in the normal course of business, may be affected from quarter to quarter by buying patterns of major distributors, seasonality and the severity of seasonal diseases and outbreaks, and foreign currency exchange rates. Revenues for the Life Science segment, in the normal course of business, may be affected from quarter to quarter by buying patterns of major customers, and foreign currency exchange rates. We believe that the overall breadth of our product lines serves to reduce the variability in consolidated revenues due to these factors.


	Three Months Ended December 31,
	2018			2017			Inc (Dec)
Diagnostics -
Americas	$	31,147		$	31,575			(1	)%
EMEA		5,085			5,415			(6	)%
ROW		433			500			(13	)%

Total Diagnostics		36,665			37,490			(2	)%

Life Science -
Americas		4,534			5,250			(14	)%
EMEA		7,455			5,185			44	%
ROW		2,826			4,358			(35	)%

Total Life Science		14,815			14,793			—	%

Consolidated	$	51,480		$	52,283			(2	)%

% of total revenues -
Diagnostics		71	%		72	%
Life Science		29	%		28	%

Total		100	%		100	%

Ex-Americas		31	%		30	%

Revenue Overview- By Product Platform/Type

The revenues generated by each of our reportable segments result primarily from the sale of the following segment-specific categories of products:

Diagnostics

Molecular assays that operate on our Alethia platform (formerly branded as illumigene)

Immunoassays and blood chemistry assays on multiple technology platforms

Life Science

Molecular reagents

Immunological reagents

Page 18

Revenues for each product platform/type, as well as its relative percentage of segment revenues, are shown below.


	Three Months Ended December 31,
	2018			2017			Inc (Dec)
Diagnostics-
Molecular assays	$	7,298		$	8,717			(16	)%
Immunoassays & blood chemistry assays		29,367			28,773			2	%

Total Diagnostics	$	36,665		$	37,490			(2	)%

Life Science-
Molecular reagents	$	6,589		$	5,688			16	%
Immunological reagents		8,226			9,105			(10	)%

Total Life Science	$	14,815		$	14,793			—	%

% of Diagnostics revenues-
Molecular assays		20	%		23	%
Immunoassays & blood chemistry assays		80	%		77	%

Total Diagnostics		100	%		100	%

% of Life Science revenues-
Molecular reagents		44	%		38	%
Immunological reagents		56	%		62	%

Total Life Science		100	%		100	%

Following is a discussion of the revenues generated by each of these product platforms/types and disease states:

Diagnostics Products

Gastrointestinal Assays

During the first quarter of fiscal 2019, revenues from our gastrointestinal products, which include tests for C. difficile, H. pylori and certain foodborne pathogens, among others, totaled $18,633. This represents an 8% decrease from the first quarter of fiscal 2018. This decrease results in large part from the pricing and volume pressures we continue to face within this product category. In an effort to combat these pressures, we have executed multi-year supply agreements with our two largest reference laboratory customers for H. pylori tests to secure volume, albeit at lower selling prices. We continue to believe there are ongoing benefits to be realized from our partnerships with managed care companies in promoting: (i) the health and economic benefits of a test and treat strategy; (ii) changes in policies that discourage the use of traditional serology methods and promote the utilization of active infection testing methods; and (iii) physician behavior movement away from serology-based testing and toward direct antigen testing.

Contributing to the competitive pressures being faced in this product category, the patents for our H. pylori products, owned by us, expired in May 2016 in the U.S. and in May 2017 in countries outside the U.S. We expect competition with respect to our H. pylori products to increase in the near future, and such competition may have an adverse impact on our selling prices for these products, or our ability to retain business at prices acceptable to us, and consequently, adversely affect our future results of operations and liquidity, including revenues and gross profit. Our product development pipeline includes new product initiatives for the detection of H. pylori, and early in the first quarter of fiscal 2019 we entered into a strategic collaboration with DiaSorin to sell H. pylori tests (see Note 10, “Litigation Matters” of the accompanying Condensed Consolidated Financial Statements). We are unable to provide assurances that we will be successful with any strategy or that any strategy will prevent an adverse effect on our future results of operations and liquidity, including revenues and gross profit.

Page 19

Respiratory Illness Assays

Including tests for influenza, RSV, Group A Strep, Pertussis, and Mycoplasma pneumonia, among others, our respiratory illness product revenues increased 7% in the fiscal 2019 first quarter.

Blood Chemistry Assays

Revenues from our sale of products to test for elevated levels of lead in blood increased 5% during the first quarter of fiscal 2019 to a total of $4,466. In late December 2018, the documents to reinstate our venous blood claims removed in fiscal 2017 were submitted to the FDA. See Note 10, “Litigation Matters” of the accompanying Condensed Consolidated Financial Statements for additional information related to the Company’s LeadCare product line.

Life Science Products

During the first quarter of fiscal 2018, revenues from our Life Science segment were flat, with revenues from molecular reagent sales increasing 16% from the comparable fiscal 2018 quarter and revenues from immunological reagent sales decreasing 10%. Our Life Science segment’s growth was slightly impacted by the movement in currency exchange rates since the first quarter of fiscal 2018, with revenues increasing 1% on a constant-currency basis over the first quarter of fiscal 2018. Our Life Science segment was also impacted by buying patterns of certain IVD manufacturer customers including sales into China, with such sales totaling approximately $1,000 during first quarter of fiscal 2019 – representing an approximate 28% decrease from the first quarter of fiscal 2018.

Significant Customers

Revenue concentrations related to certain customers within our Diagnostics and Life Science segments are set forth in Note 9 of the accompanying Condensed Consolidated Financial Statements.

Gross Profit


	Three Months Ended December 31,
	2018			2017			Change
Gross Profit	$	31,572		$	32,010			(1	)%
Gross Profit Margin		61	%		61	%		—

Operating Expenses – Segment Detail


	Research & Development		Selling & Marketing		General & Administrative		Other		Total Operating Expenses
Fiscal 2018 First Quarter:
Diagnostics	$	3,705	$	6,456	$	5,114	$	—	$	15,275
Life Science		715		2,388		2,016		—		5,119
Corporate		—		—		2,072		1,483		3,555

Total 2018 First Quarter Expenses	$	4,420	$	8,844	$	9,202	$	1,483	$	23,949

Fiscal 2019 First Quarter:
Diagnostics	$	3,196	$	6,041	$	4,609	$	—	$	13,846
Life Science		771		1,522		1,491		—		3,784
Corporate		—		—		2,802		589		3,391

Total 2019 First Quarter Expenses	$	3,967	$	7,563	$	8,902	$	589	$	21,021

Page 20

Operating Expenses – Comparison to Prior Year Periods


	Research & Development			Selling & Marketing			General & Administrative			Other			Total Operating Expenses
2018 First Quarter Expenses	$	4,420		$	8,844		$	9,202		$	1,483		$	23,949

% of Revenues		8	%		17	%		18	%		3	%		46	%
Fiscal 2019 Increases (Decreases):
Diagnostics		(509	)		(415	)		(505	)		—			(1,429	)
Life Science		56			(866	)		(525	)		—			(1,335	)
Corporate		—			—			730			(894	)		(164	)

2019 First Quarter Expenses	$	3,967		$	7,563		$	8,902		$	589		$	21,021

% of Revenues		8	%		15	%		17	%		1	%		41	%
% Increase (Decrease)		(10	)%		(14	)%		(3	)%		(60	)%		(12	)%

Total operating expenses decreased during the first quarter of fiscal 2019 compared to the first quarter of fiscal 2018, with overall decreases in spending in all of our segments, reflecting the following:

•

Decreased Research & Development costs due to the timing of product development projects and the clinical trials for our cCMV test in the first quarter of fiscal 2018;

•

Decreased Selling & Marketing costs due to: (i) lower sales commissions resulting from the decrease in sales levels; and (ii) the effects of the fiscal 2018 organization streamlining initiatives;

•

Decreased General & Administrative costs due to: (i) lower Quality System remediation costs related to our blood-lead manufacturing facility; and (ii) the effects of the fiscal 2018 organization streamlining initiatives; and

•

Decreased restructuring & litigation costs (reflected with “Other” in the above tables), noting that the only such costs incurred during the fiscal 2019 first quarter were litigation costs related to the matters discussed in Note 10 of the accompanying Condensed Consolidated Financial Statements.

Operating Income

Operating income increased 31% to $10,551 for the first quarter of fiscal 2019, as a result of the factors discussed above, including the restructuring and litigation costs.

Income Taxes

The effective rate for income taxes was 23% for the first quarter of fiscal 2019, compared to 18% for the first quarter of 2018. This higher fiscal 2019 tax results from the fact that the fiscal 2019 first quarter reflects the lower U.S. federal tax rate of 21% being fully phased-in, while the fiscal 2018 first quarter reflects the combined net impact of the following effects of the tax reform act (see Note 7 of the accompanying Condensed Consolidated Financial Statements):

•

Application of an approximate 24.5% blended rate due to the lowering of the applicable rate from 35% to 21% on a phased-in basis;

•

Recognizing a one-time $1,695 tax benefit, including the re-measurement of deferred tax balances at the lower rate; and

•

Recording a provisional one-time $854 tax expense related to the estimated repatriation transition tax on foreign earnings.

Page 21

Liquidity and Capital Resources

Comparative Cash Flow Analysis

Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets, debt service, consideration of acquisition plans, and consideration of common share dividends. We have historically maintained a credit facility to augment working capital requirements and to respond quickly to acquisition opportunities.

We have an investment policy that guides the holdings of our investment portfolio, which presently consists of bank savings accounts and institutional money market mutual funds. Our objectives in managing the investment portfolio are to: (i) preserve capital; (ii) provide sufficient liquidity to meet working capital requirements and fund strategic objectives such as acquisitions; and (iii) capture a market rate of return commensurate with market conditions and our policy’s investment eligibility criteria. As we look forward, we will continue to manage the holdings of our investment portfolio with preservation of capital being the primary objective.

Considering the various worldwide geo-political and geo-economic conditions, we do not expect macroeconomic conditions to have a significant impact on our liquidity needs, financial condition or results of operations, although no assurances can be made in this regard. We intend to continue to fund our working capital requirements and dividends from current cash flows from operating activities and cash on hand. If needed, we also have an additional source of liquidity through our $30,000 bank revolving credit facility. Our liquidity needs may change if overall economic conditions worsen and/or liquidity and credit within the financial markets tightens for an extended period of time, and such conditions impact the collectability of our customer accounts receivable, impact credit terms with our vendors, or disrupt the supply of raw materials and services.

As of December 31, 2018, our cash and equivalents balance is $61,523 or $6,812 higher than at the end of the fiscal 2018 first quarter, and $1,760 higher than at September 30, 2018. This increase results in large part from the cash flows from operating activities being more than sufficient to cover capital expenditures, shareholder dividends and debt service. Net cash flows from operating activities and cash on hand are anticipated to be adequate to fund working capital requirements, capital expenditures and shareholder dividends during the next 12 months.

The indicated annual cash dividend rate for fiscal 2019 was established at $0.50 per share. Consistent with this annual indicated dividend rate, a cash dividend of $0.125 was declared for the first quarter of fiscal 2019.

Capital Resources

In 2016, the Company entered into a $60,000 five-year term loan and related interest rate swap agreement with a commercial bank, the details of which are set forth in Note 8 of the accompanying Condensed Consolidated Financial Statements. In addition, we have a $30,000 revolving credit facility (discussed above) with a commercial bank that expires March 31, 2021. As of January 31, 2019, there were no borrowings outstanding on this facility and we had 100% borrowing capacity available to us. We have had no borrowings outstanding under this revolving credit facility during the first three months of fiscal 2019 or during the full year of fiscal 2018.

Our capital expenditures are estimated to range between approximately $4,000 to $5,000 for fiscal 2019, with the actual amount dependent upon actual operating results and the phasing of certain projects. Such expenditures may be funded with cash and equivalents on hand, operating cash flows, and/or availability under the $30,000 revolving credit facility discussed above.

We do not utilize any special-purpose financing vehicles or have any undisclosed off-balance sheet arrangements.

Page 22

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in the Company’s exposure to market risk since September 30, 2018.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of December 31, 2018. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2018.

Changes in Internal Control over Financial Reporting

During the quarter ended December 31, 2018, the Company enacted additional controls associated with the adoption of ASU 2014-09, Revenue from Contracts with Customers. There were no other changes in our internal control over financial reporting (as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 10 of the accompanying Condensed Consolidated Financial Statements.

ITEM 1A. RISK FACTORS

There have been no material changes from risk factors as previously disclosed in the Company’s fiscal 2018 Annual Report on Form 10-K in response to Item 1A to Part I of Form 10-K.

ITEM 6. EXHIBITS

The following exhibits are being filed or furnished as a part of this Quarterly Report on Form 10-Q.



31.1		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)

31.2		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)

32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101		The following financial information from Meridian Bioscience Inc.’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2018 filed with the SEC on February 11, 2019, formatted in XBRL includes: (i) Condensed Consolidated Statements of Operations for the three months ended December 31, 2018 and 2017; (ii) Condensed Consolidated Statements of Comprehensive Income for the three months ended December 31, 2018 and 2017; (iii) Condensed Consolidated Statements of Cash Flows for the three months ended December 31, 2018 and 2017; (iv) Condensed Consolidated Balance Sheets as of December 31, 2018 and September 30, 2018; (v) Condensed Consolidated Statements of Shareholders’ Equity for the three months ended December 31, 2018 and 2017; and (vi) the Notes to Condensed Consolidated Financial Statements

Page 23

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Page 24

EX-31.1 2 d627978dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)

I, Jack Kenny, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Meridian Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 11, 2019

/s/ Jack Kenny

Jack Kenny

Chief Executive Officer

EX-31.2 3 d627978dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)

I, Eric S. Rasmussen, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Meridian Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 11, 2019

/s/ Eric S. Rasmussen

Eric S. Rasmussen

Executive Vice President and Chief Financial Officer

EX-32 4 d627978dex32.htm EX-32 EX-32

Exhibit 32

Meridian Bioscience, Inc.

Certification of Chief Executive Officer and Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing with the Securities and Exchange Commission of the Quarterly Report of Meridian Bioscience, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2018 (the “Report”), the undersigned officers of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Jack Kenny

Jack Kenny

Chief Executive Officer

February 11, 2019

/s/ Eric S. Rasmussen

Eric S. Rasmussen

Executive Vice President and

Chief Financial Officer

February 11, 2019

EX-101.INS 5 vivo-20181231.xml XBRL INSTANCE DOCUMENT 42489202

60000000

54711000

55711000

1000000

172878000

127367000

-2426000

42307000

47937000

3035000

139614000

1023000

736000

331000

64108000

130876000

6228000

-4525000

249857000

32443000

61523000

71000000

1000000

62523000

42488602

121000

3861000

1145000

0.0276

60000000

4779000

33721000

2182000

2166000

2170000

2560000

3156000

55986000

54403000

2487000

12037000

22265000

41889000

7123000

20690000

1158000

249857000

50525000

5625000

30000000

43438000

452000

79386000

30857000

1000000

4411000

1000000

94965000

31791000

52291000

178642000

1727000 2490000 59637000

39000000

6000000

4125000

40983000

20540000

1000000

-289000

71283000

19190000

879000

178863000

35213000

21386000

720000

5463000

8613000

13295000

24385000

14243000

22268000

1224000

21505000

P1Y

8000

368000

5000

381000

130876000

-4525000

42489000

52291000

58072000

169585000

125608000

-2946000

42207000

46923000

5065000

139053000

335000

441000

310000

55846000

129193000

6260000

-3377000

251377000

32444000

59763000

71000000

60763000

42399962

130000

3769000

1722000

7263000

33012000

56125000

54637000

12098000

23113000

41993000

6689000

24173000

1160000

251377000

51786000

5250000

44930000

488000

82329000

29995000

1000000

4961000

1000000

85841000

32336000

49602000

175418000

1631000 2646000 1239000 50606000

39342000

20421000

1000000

58000

70341000

19424000

1045000

180978000

35213000

22068000

720000

5267000

8647000

13051000

24461000

13974000

22297000

1191000

22015000

33000

987000

6000

1026000

129193000

-3377000

42400000

49602000

63457000

3731000

49486000

59302000

7611000

38000

-116000

-1239000 8696000

-116000

P3Y

0.12

6332000

1034000

1759000

938000

0.125

-2361000

0.125

6822000

20273000

-1624000

1146000

5288000

0.15

115000

0.15

9202000

7658000

1356000

-87000

32010000

1315000

497000

2989000

395000

2353000

108000

72000

749000

-403000

-1234000

-6413000

5171000

6302000

520000

112000

-80000

341000

291000

23949000

229000

8061000

291000

5288000

1234000

6302000

4420000

1125000

734000

52283000

1759000

8844000

42662000

42263000

399000

-1695000 854000 201000 0.245

-3555000

1483000

104000

-313000

2943000

14793000

192000

8569000

37490000

121000

0.23

0.32

0.15

730000

8717000

28773000

5688000

9105000

20270000

7486000

4266000

5468000

1759000

291000

229000

100000

5288000

6302000

5250000

31575000

5185000

5415000

4358000

500000

14793000

37490000

684000

false

1670000

829000

0.125

1760000

0.125

6958000

19908000

--09-30

96000

1253000

5301000

Q1 2019 10-Q

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Revenue by Reportable Segment & Geographic Region <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Americas </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 31,147</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 31,575</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> EMEA </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,085</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,415</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> ROW </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">433</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(13</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Life Science- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Americas </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,534</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,250</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> EMEA </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,455</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,185</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> ROW </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,826</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,358</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(35</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total Life Science </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,815</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,793</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Consolidated </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 51,480</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 52,283</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Revenue by Product Platform/Type <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Molecular assays </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,298</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,717</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Immunoassays & blood chemistry assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,367</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,773</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Life Science- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Molecular reagents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,589</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,688</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Immunological reagents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,226</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,105</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total Life Science </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 14,815</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 14,793</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Revenue by Disease State (Diagnostics only) <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Gastrointestinal assays </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 18,633</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 20,270</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Respiratory illness assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,977</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,486</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Blood chemistry assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,466</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,266</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,589</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,468</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.19

0000794172

-257000

MERIDIAN BIOSCIENCE INC false 2018-12-31

0.19

false Large Accelerated Filer

8902000

10476000

2370000

-539000

31572000

-4081000

991000

-317000

363000

37000

276000

149000

589000

2021-03-31

-75000

-1109000

-6281000

9407000

8106000

-1148000

-145000

139000

-577000

-716000

21021000

-432000

10551000

-716000

5301000

1109000

8106000

3967000

1125000

30 to 90 days from the date of shipment or satisfaction of the performance obligation

<div> Revenue Recognition – Adoption of New Standard On October 1, 2018, we adopted ASU No. 2014-09, Revenue from Contracts with Customers, using the modified retrospective transition method applied to those contracts that were not completed as of that date. Results for reporting periods beginning on or after October 1, 2018 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previously applicable guidance. Upon adoption, we recorded a reduction of $116 to the opening balance of retained earnings as of October 1, 2018. This adjustment is related to writing off the book value of clinical diagnostic testing instruments located at customers for which there is no contractual arrangement for the instrument to be returned to the Company. Instruments placed with customers under an agreement to return the instrument to the Company were reclassified to machinery and equipment. Prior to adoption of the new guidance, all instruments placed with customers were capitalized and amortized over an estimated three-year utilization period, with the net balance reflected as deferred instrument costs.   The following table summarizes the impact of the new revenue standard on our opening balance sheet:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Balance at September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">New Revenue Standard Adjustment</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Balance at October 1, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> PROPERTY, PLAN AND EQUIPMENT </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Machinery, equipment and furniture </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50,606</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,696</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">59,302</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(55,846</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,611</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(63,457</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OTHER ASSETS </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred instrument costs, net </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,239</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> NON-CURRENT LIABILITIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,769</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,731</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> SHAREHOLDERS’ EQUITY </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Retained earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,602</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,486</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> The adoption of this new standard had an immaterial impact on our reported total revenues and operating income, as compared to what would have been reported under the prior standard. We expect the impact of adoption in future periods to continue to be immaterial. Our accounting policies under the new standard were applied prospectively and are noted below following the discussion of Revenue Disaggregation. Revenue Disaggregation The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only): Revenue by Reportable Segment & Geographic Region   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Americas </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 31,147</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 31,575</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> EMEA </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,085</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,415</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> ROW </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">433</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(13</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Life Science- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Americas </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,534</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,250</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> EMEA </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,455</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,185</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> ROW </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,826</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,358</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(35</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Life Science </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,815</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,793</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Consolidated </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 51,480</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 52,283</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Revenue by Product Platform/Type   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Molecular assays </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,298</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,717</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Immunoassays & blood chemistry assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,367</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,773</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Life Science- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Molecular reagents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,589</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,688</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Immunological reagents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,226</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,105</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Life Science </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 14,815</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 14,793</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Revenue by Disease State (Diagnostics only)   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Gastrointestinal assays </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 18,633</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 20,270</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Respiratory illness assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,977</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,486</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Blood chemistry assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,466</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,266</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,589</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,468</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Revenue Policies Product Sales Revenue from contracts with customers is recognized in an amount that reflects the consideration we expect to receive in exchange for products when obligations under such contracts are satisfied. Revenue is generally recognized at a point-in-time when products are shipped and title has passed to the customer. Such contracts can include various combinations of products that are generally accounted for as distinct performance obligations. Revenue is reduced in the period of sale for fees paid to distributors, which are inseparable from the distributor’s purchase of our product and for which we receive no goods or services in return. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments due to certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals are netted against accounts receivable. Shipping and handling costs incurred after control of the product is transferred to our customers are treated as fulfillment costs and not a separate performance obligation. Our payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 90 days from the date of shipment or satisfaction of the performance obligation. Trade accounts receivable are recorded in the accompanying Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience and known conditions that would likely lead to non-payment. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid.   Practical Expedients and Exemptions Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable. We expense as incurred the costs to obtain contracts, as the amortization period would have been one year or less. These costs, recorded within selling and marketing expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Reagent Rental Arrangements Our Alethia and LeadCare product platforms require the use of instruments for the tests to be processed. In many cases a customer is given use of the instrument, provided they continue purchasing the associated tests, also referred to as “consumables” or “reagents”. If a customer stops purchasing the consumables, the instrument must be returned to Meridian. Such arrangements are common practice in the diagnostics industry and are referred to as “Reagent Rental” agreements. These agreements may also include instrument related services such as a limited replacement warranty, training and installation. We concluded that the use of the instrument and related services (collectively known as “lease elements”) are not within the scope of ASU No. 2014-09 but rather ASU 2016-02, Leases. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on estimates of relative standalone selling prices. Lease revenue is derived solely from the sale of consumables and is therefore recognized monthly as earned, which coincides with the transfer of control of the non-lease elements. For the portion of the transaction price allocated to the non-lease elements, which are principally the test kits, the related revenue will be recognized at a point-in-time when control transfers. Revenue allocated to the lease elements of these Reagent Rental arrangements represent less than 1% of total revenue and are included as part of net revenues in our Condensed Consolidated Statements of Income. </div>

51480000

1670000

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left"> Significant Accounting Policies </td> </tr> </table> A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 2018 Annual Report on Form 10-K and should be referred to for a description of the Company’s current significant accounting policies, with the exception of Revenue Recognition, which is set forth below. Revenue Recognition – Adoption of New Standard On October 1, 2018, we adopted ASU No. 2014-09, Revenue from Contracts with Customers, using the modified retrospective transition method applied to those contracts that were not completed as of that date. Results for reporting periods beginning on or after October 1, 2018 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previously applicable guidance. Upon adoption, we recorded a reduction of $116 to the opening balance of retained earnings as of October 1, 2018. This adjustment is related to writing off the book value of clinical diagnostic testing instruments located at customers for which there is no contractual arrangement for the instrument to be returned to the Company. Instruments placed with customers under an agreement to return the instrument to the Company were reclassified to machinery and equipment. Prior to adoption of the new guidance, all instruments placed with customers were capitalized and amortized over an estimated three-year utilization period, with the net balance reflected as deferred instrument costs.   The following table summarizes the impact of the new revenue standard on our opening balance sheet:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Balance at September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">New Revenue Standard Adjustment</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Balance at October 1, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> PROPERTY, PLAN AND EQUIPMENT </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Machinery, equipment and furniture </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50,606</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,696</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">59,302</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(55,846</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,611</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(63,457</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OTHER ASSETS </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred instrument costs, net </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,239</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> NON-CURRENT LIABILITIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,769</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,731</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> SHAREHOLDERS’ EQUITY </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Retained earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,602</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,486</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> The adoption of this new standard had an immaterial impact on our reported total revenues and operating income, as compared to what would have been reported under the prior standard. We expect the impact of adoption in future periods to continue to be immaterial. Our accounting policies under the new standard were applied prospectively and are noted below following the discussion of Revenue Disaggregation. Revenue Disaggregation The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only): Revenue by Reportable Segment & Geographic Region   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Americas </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 31,147</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 31,575</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> EMEA </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,085</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,415</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> ROW </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">433</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">500</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(13</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Life Science- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Americas </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,534</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,250</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> EMEA </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,455</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,185</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> ROW </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,826</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,358</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(35</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Life Science </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,815</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,793</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Consolidated </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 51,480</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 52,283</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Revenue by Product Platform/Type   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Molecular assays </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,298</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,717</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Immunoassays & blood chemistry assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,367</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28,773</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Life Science- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Molecular reagents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,589</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,688</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Immunological reagents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,226</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,105</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Life Science </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 14,815</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 14,793</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Revenue by Disease State (Diagnostics only)   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> Three Months Ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Inc (Dec)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Diagnostics- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Gastrointestinal assays </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 18,633</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 20,270</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Respiratory illness assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,977</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,486</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Blood chemistry assays </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,466</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,266</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,589</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,468</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Diagnostics </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2</td> <td valign="bottom" nowrap="nowrap">)% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Revenue Policies Product Sales Revenue from contracts with customers is recognized in an amount that reflects the consideration we expect to receive in exchange for products when obligations under such contracts are satisfied. Revenue is generally recognized at a point-in-time when products are shipped and title has passed to the customer. Such contracts can include various combinations of products that are generally accounted for as distinct performance obligations. Revenue is reduced in the period of sale for fees paid to distributors, which are inseparable from the distributor’s purchase of our product and for which we receive no goods or services in return. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments due to certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals are netted against accounts receivable. Shipping and handling costs incurred after control of the product is transferred to our customers are treated as fulfillment costs and not a separate performance obligation. Our payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 90 days from the date of shipment or satisfaction of the performance obligation. Trade accounts receivable are recorded in the accompanying Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience and known conditions that would likely lead to non-payment. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid.   Practical Expedients and Exemptions Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable. We expense as incurred the costs to obtain contracts, as the amortization period would have been one year or less. These costs, recorded within selling and marketing expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Reagent Rental Arrangements Our Alethia and LeadCare product platforms require the use of instruments for the tests to be processed. In many cases a customer is given use of the instrument, provided they continue purchasing the associated tests, also referred to as “consumables” or “reagents”. If a customer stops purchasing the consumables, the instrument must be returned to Meridian. Such arrangements are common practice in the diagnostics industry and are referred to as “Reagent Rental” agreements. These agreements may also include instrument related services such as a limited replacement warranty, training and installation. We concluded that the use of the instrument and related services (collectively known as “lease elements”) are not within the scope of ASU No. 2014-09 but rather ASU 2016-02, Leases. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on estimates of relative standalone selling prices. Lease revenue is derived solely from the sale of consumables and is therefore recognized monthly as earned, which coincides with the transfer of control of the non-lease elements. For the portion of the transaction price allocated to the non-lease elements, which are principally the test kits, the related revenue will be recognized at a point-in-time when control transfers. Revenue allocated to the lease elements of these Reagent Rental arrangements represent less than 1% of total revenue and are included as part of net revenues in our Condensed Consolidated Statements of Income. Recent Accounting Pronouncements – In February 2016, the FASB issued ASU 2016-02, Leases, which amends the accounting guidance related to leases. These changes, which are designed to increase transparency and comparability among organizations for both lessees and lessors, include, among other things, requiring recognition of lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2020, although early adoption is permitted. The Company expects to begin its assessment of the impact that adoption of this guidance will have on its financial statements during the second quarter of fiscal 2019. In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. The update addresses certain specific cash flows and their treatment, with the objective being to reduce the existing diversity in how the items are presented and classified within the statement of cash flows. The Company adopted this guidance in the first quarter of fiscal 2019, with the Condensed Consolidated Statements of Cash Flows reflecting such adoption, including the information related to restricted cash. In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, to address certain of the recent U.S. federal income tax legislation’s impact on Accumulated Other Comprehensive Income (“AOCI”). The guidance specifically provides the option of reclassifying “stranded tax effects” related to the tax legislation from AOCI to retained earnings. Adoption and implementation of the optional guidance is not effective for the Company until the beginning of fiscal 2020, although early adoption is permitted. The Company plans to adopt this guidance in fiscal 2020 as required but does not expect adoption to have a significant impact on the Company’s consolidated results of operations, cash flows or financial position.   Reclassifications – Certain reclassifications have been made to the prior year financial statements to conform to the current year presentation. Such reclassifications had no impact on net earnings or shareholders’ equity. </div>

7563000

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left">9.</td> <td valign="top" align="left"> Reportable Segment and Major Customers Information </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Meridian was formed in 1976 and functions as a fully-integrated life science company with principal businesses in: (i) the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers and other diagnostic manufacturers. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio, and manufacturing operations for blood chemistry products in Billerica, Massachusetts (near Boston), and the sale and distribution of diagnostics products domestically and abroad. This segment’s products are used by hospitals, reference labs and physician offices to detect infectious diseases and elevated lead levels in blood. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents domestically and abroad, including a sales and business development facility in Beijing, China to further pursue growing revenue opportunities in Asia. This segment’s products are used by manufacturers and researchers in a variety of applications (e.g., in-vitro medical device manufacturing, microRNA detection, next-gen sequencing, plant genotyping, and mutation detection, among others). <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Amounts due from two Diagnostics distributor customers accounted for 14% and 12% of consolidated accounts receivable at December 31, 2018 and September 30, 2018, respectively. Revenues from these two distributor customers accounted for 34% and 32% of the Diagnostics segment third-party revenues during the three months ended December 31, 2018 and 2017, respectively, and represented 24% and 23% of consolidated revenues for the fiscal 2019 and 2018 first quarters, respectively. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Within our Life Science segment, two diagnostic manufacturing customers accounted for 28% and 15% of the segment’s third-party revenues during the three months ended December 31, 2018 and 2017, respectively. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Segment information for the interim periods is as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Diagnostics</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Life Science</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Corporate(1)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Eliminations(2)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended December 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues - </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Third-Party </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,665</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 14,815</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,480</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Inter-segment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">163</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">176</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(339</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,786</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,129</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,391</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,551</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Goodwill (December 31, 2018) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,213</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,190</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">54,403</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other intangible assets, net (December 31, 2018) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,386</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">879</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,265</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total assets (December 31, 2018) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178,863</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71,283</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(289</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">249,857</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Three Months Ended December 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Net revenues - </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Third-Party </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,490</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 14,793</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">52,283</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Inter-segment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">121</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">192</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(313</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Operating income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,569</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,943</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,555</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,061</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Goodwill (September 30, 2018) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,213</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,424</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">54,637</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other intangible assets, net (September 30, 2018) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,068</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,045</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,113</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total assets (September 30, 2018) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">180,978</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70,341</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">251,377</td> <td valign="bottom" nowrap="nowrap"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left"> Includes Restructuring and Litigation Costs of $589 and $1,483 in the quarters ended December 31, 2018 and 2017, respectively. </td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left"> Eliminations consist of inter-segment transactions. </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation. </div>

<div> The following table summarizes the impact of the new revenue standard on our opening balance sheet:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Balance at September 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">New Revenue Standard Adjustment</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Balance at October 1, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> PROPERTY, PLAN AND EQUIPMENT </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Machinery, equipment and furniture </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50,606</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,696</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">59,302</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accumulated depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(55,846</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,611</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(63,457</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> OTHER ASSETS </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred instrument costs, net </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,239</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> NON-CURRENT LIABILITIES </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Deferred income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,769</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,731</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> SHAREHOLDERS’ EQUITY </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Retained earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,602</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,486</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> </div>

VIVO

42905000

42446000

459000

145000 13000 876000 500000 (i) notional reduction amounts and dates; (ii) LIBOR settlement rates; (iii) rate reset dates; and (iv) term/maturity. <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> A summary of the accrued liability associated with the restructuring costs as of December 31, 2018 and September 30, 2018, is as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Severance, other termination benefits and related costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 368</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">987</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Lease and other contract termination fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 381</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> 1,026</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 0.21 -0.02

-116000

736000 140000

-3391000

589000

27000

-339000

5129000

14815000

176000

8786000

36665000

163000

0.14

0.24

0.01

0.34

0.28

50000

2017-11-15

2017-12-06

2018-04-16

540000

2018-04-17

7298000

-0.16

29367000

0.02

6589000

0.16

8226000

-0.10

18633000

-0.08

7977000

0.07

4466000

0.05

5589000

0.02

1670000

13000

-716000

-432000

89000

5301000

8106000

4534000

-0.14

31147000

-0.01

7455000

0.44

5085000

-0.06

2826000

-0.35

433000

-0.13

14815000

36665000

-0.02 0000794172 vivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:LifeScienceMember 2018-10-01 2018-12-31 0000794172 vivo:OtherForeignMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:OtherForeignMembervivo:LifeScienceMember 2018-10-01 2018-12-31 0000794172 us-gaap:EMEAMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 us-gaap:EMEAMembervivo:LifeScienceMember 2018-10-01 2018-12-31 0000794172 srt:AmericasMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 srt:AmericasMembervivo:LifeScienceMember 2018-10-01 2018-12-31 0000794172 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000794172 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2018-12-31 0000794172 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000794172 vivo:OtherDiagnosticsMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:BloodChemistryAssaysMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:RespiratoryIllnessAssaysMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:GastrointestinalAssaysMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:ImmunologicalReagentsMembervivo:LifeScienceMember 2018-10-01 2018-12-31 0000794172 vivo:MolecularReagentsMembervivo:LifeScienceMember 2018-10-01 2018-12-31 0000794172 vivo:ImmunoassaysAndBloodChemistryAssaysMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:MolecularAssaysMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:DojSubpoenaMember 2018-10-01 2018-12-31 0000794172 vivo:AmendedComplaintMember 2018-10-01 2018-12-31 0000794172 vivo:ClassActionComplaintTwoMember 2018-10-01 2018-12-31 0000794172 vivo:ClassActionComplaintOneMember 2018-10-01 2018-12-31 0000794172 vivo:DiasorinIncMember 2018-10-01 2018-12-31 0000794172 vivo:TwoDiagnosticManufacturingCustomersMemberus-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:LifeScienceMember 2018-10-01 2018-12-31 0000794172 vivo:TwoDiagnosticDistributorCustomersMemberus-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 vivo:TwoDiagnosticDistributorCustomersMemberus-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMember 2018-10-01 2018-12-31 0000794172 srt:MaximumMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembervivo:ReagentRentalArrangementsMembervivo:LeaseElementsMember 2018-10-01 2018-12-31 0000794172 vivo:TwoDiagnosticDistributorCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2018-10-01 2018-12-31 0000794172 vivo:TwoDiagnosticDistributorCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2018-10-01 2018-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:DiagnosticsMember 2018-10-01 2018-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:LifeScienceMember 2018-10-01 2018-12-31 0000794172 us-gaap:IntersegmentEliminationMember 2018-10-01 2018-12-31 0000794172 us-gaap:CorporateNonSegmentMember 2018-10-01 2018-12-31 0000794172 vivo:AccruedIncomeTaxesCurrentMember 2018-10-01 2018-12-31 0000794172 vivo:AccruedIncomeTaxesNoncurrentMember 2018-10-01 2018-12-31 0000794172 us-gaap:AccountingStandardsUpdate201409Memberus-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000794172 us-gaap:AccountingStandardsUpdate201409Member 2018-10-01 2018-12-31 0000794172 2018-10-01 2018-12-31 0000794172 vivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:LifeScienceMember 2017-10-01 2017-12-31 0000794172 vivo:OtherForeignMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:OtherForeignMembervivo:LifeScienceMember 2017-10-01 2017-12-31 0000794172 us-gaap:EMEAMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 us-gaap:EMEAMembervivo:LifeScienceMember 2017-10-01 2017-12-31 0000794172 srt:AmericasMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 srt:AmericasMembervivo:LifeScienceMember 2017-10-01 2017-12-31 0000794172 us-gaap:RetainedEarningsMember 2017-10-01 2017-12-31 0000794172 us-gaap:CommonStockMember 2017-10-01 2017-12-31 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-10-01 2017-12-31 0000794172 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2017-12-31 0000794172 vivo:OtherDiagnosticsMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:BloodChemistryAssaysMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:RespiratoryIllnessAssaysMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:GastrointestinalAssaysMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:ImmunologicalReagentsMembervivo:LifeScienceMember 2017-10-01 2017-12-31 0000794172 vivo:MolecularReagentsMembervivo:LifeScienceMember 2017-10-01 2017-12-31 0000794172 vivo:ImmunoassaysAndBloodChemistryAssaysMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:MolecularAssaysMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:DojSubpoenaMember 2017-10-01 2017-12-31 0000794172 vivo:ClassActionComplaintTwoMember 2017-10-01 2017-12-31 0000794172 vivo:ClassActionComplaintOneMember 2017-10-01 2017-12-31 0000794172 vivo:DiasorinIncMember 2017-10-01 2017-12-31 0000794172 vivo:TwoDiagnosticManufacturingCustomersMemberus-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:LifeScienceMember 2017-10-01 2017-12-31 0000794172 vivo:TwoDiagnosticDistributorCustomersMemberus-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 vivo:TwoDiagnosticDistributorCustomersMemberus-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMember 2017-10-01 2017-12-31 0000794172 vivo:TwoDiagnosticDistributorCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2017-10-01 2017-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:DiagnosticsMember 2017-10-01 2017-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:LifeScienceMember 2017-10-01 2017-12-31 0000794172 us-gaap:IntersegmentEliminationMember 2017-10-01 2017-12-31 0000794172 us-gaap:CorporateNonSegmentMember 2017-10-01 2017-12-31 0000794172 2017-10-01 2017-12-31 0000794172 vivo:DiagnosticsAndLifeScienceRestructuringMember 2017-10-01 2018-09-30 0000794172 vivo:TwoDiagnosticDistributorCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2017-10-01 2018-09-30 0000794172 2017-10-01 2018-09-30 0000794172 us-gaap:AccountingStandardsUpdate201409Member 2018-10-01 2018-10-01 0000794172 us-gaap:AccountingStandardsUpdate201409Memberus-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-10-01 0000794172 2018-10-01 0000794172 us-gaap:RetainedEarningsMember 2018-09-30 0000794172 us-gaap:CommonStockMember 2018-09-30 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000794172 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000794172 vivo:DiagnosticsAndLifeScienceRestructuringMember 2018-09-30 0000794172 us-gaap:OtherRestructuringMembervivo:DiagnosticsAndLifeScienceRestructuringMember 2018-09-30 0000794172 us-gaap:EmployeeSeveranceMembervivo:DiagnosticsAndLifeScienceRestructuringMember 2018-09-30 0000794172 us-gaap:ContractTerminationMembervivo:DiagnosticsAndLifeScienceRestructuringMember 2018-09-30 0000794172 vivo:KitsAndReagentsMember 2018-09-30 0000794172 vivo:InstrumentsMember 2018-09-30 0000794172 vivo:ManufacturingTechnologiesCoreProductsAndCellLinesMember 2018-09-30 0000794172 vivo:CustomerListsAndRelationshipsAndSupplyAgreementsMember 2018-09-30 0000794172 vivo:TradeNamesLicensesAndPatentsMember 2018-09-30 0000794172 us-gaap:NoncompeteAgreementsMember 2018-09-30 0000794172 us-gaap:OperatingSegmentsMembervivo:DiagnosticsMember 2018-09-30 0000794172 us-gaap:OperatingSegmentsMembervivo:LifeScienceMember 2018-09-30 0000794172 us-gaap:IntersegmentEliminationMember 2018-09-30 0000794172 vivo:OtherRestrictedCashMember 2018-09-30 0000794172 us-gaap:MoneyMarketFundsMember 2018-09-30 0000794172 us-gaap:CashMember 2018-09-30 0000794172 2018-09-30 0000794172 us-gaap:RetainedEarningsMember 2017-09-30 0000794172 us-gaap:CommonStockMember 2017-09-30 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0000794172 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000794172 2017-09-30 0000794172 us-gaap:RetainedEarningsMember 2018-12-31 0000794172 us-gaap:CommonStockMember 2018-12-31 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000794172 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000794172 vivo:DiagnosticsAndLifeScienceRestructuringMember 2018-12-31 0000794172 us-gaap:OtherRestructuringMembervivo:DiagnosticsAndLifeScienceRestructuringMember 2018-12-31 0000794172 us-gaap:EmployeeSeveranceMembervivo:DiagnosticsAndLifeScienceRestructuringMember 2018-12-31 0000794172 us-gaap:ContractTerminationMembervivo:DiagnosticsAndLifeScienceRestructuringMember 2018-12-31 0000794172 srt:MaximumMember 2018-12-31 0000794172 vivo:KitsAndReagentsMember 2018-12-31 0000794172 vivo:InstrumentsMember 2018-12-31 0000794172 vivo:ManufacturingTechnologiesCoreProductsAndCellLinesMember 2018-12-31 0000794172 vivo:CustomerListsAndRelationshipsAndSupplyAgreementsMember 2018-12-31 0000794172 vivo:TradeNamesLicensesAndPatentsMember 2018-12-31 0000794172 us-gaap:NoncompeteAgreementsMember 2018-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:DiagnosticsMember 2018-12-31 0000794172 us-gaap:OperatingSegmentsMembervivo:LifeScienceMember 2018-12-31 0000794172 us-gaap:IntersegmentEliminationMember 2018-12-31 0000794172 vivo:OtherRestrictedCashMember 2018-12-31 0000794172 us-gaap:MoneyMarketFundsMember 2018-12-31 0000794172 us-gaap:CashMember 2018-12-31 0000794172 vivo:MagellanMember 2018-12-31 0000794172 2018-12-31 0000794172 us-gaap:RetainedEarningsMember 2017-12-31 0000794172 us-gaap:CommonStockMember 2017-12-31 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000794172 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000794172 2017-12-31 0000794172 vivo:MagellanMembervivo:FiveYearTermLoanMember 2016-03-22 0000794172 2019-01-31 shares iso4217:USD iso4217:USD shares pure vivo:Customer

EX-101.SCH 6 vivo-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Condensed Consolidated Statements of Changes in Shareholders Equity (Unaudited) link:calculationLink link:presentationLink link:definitionLink 109 - Statement - Condensed Consolidated Statements of Changes in Shareholders Equity (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Cash and Equivalents link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Restructuring link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Bank Credit Arrangements link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Reportable Segment and Major Customers Information link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Litigation Matters link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Cash and Equivalents (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Restructuring (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Reportable Segment and Major Customers Information (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Significant Accounting Policies - Summary of Impact of New Revenue Standard on Opening Balance Sheet (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Significant Accounting Policies - Summary of Disaggregation of Revenue by Reportable Segment and Geographic Region (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Significant Accounting Policies - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Significant Accounting Policies - Summary of Disaggregation of Revenue by Disease State (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Inventories - Components of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Intangible Assets- Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Restructuring - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Restructuring - Schedule of Accrued Liability Associated With Restructuring Costs (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Bank Credit Arrangements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Reportable Segment and Major Customers Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Reportable Segment and Major Customers Information - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Reportable Segment and Major Customers Information - Segment Information (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Litigation Matters - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 vivo-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 vivo-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 vivo-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Accounts Payable, Current Accounts payable Accounts Receivable [Member] Consolidated Accounts Receivable [Member] Accrued Income Taxes, Current Income taxes payable Accrued Income Taxes Current [Member] Accrued Income Taxes Current [Member] Accrued Income Taxes Current [Member] Accrued Income Taxes, Noncurrent Long-term income taxes payable Accrued Income Taxes Noncurrent [Member] Accrued Income Taxes Noncurrent [Member] Accrued Income Taxes Noncurrent [Member] Accrued Liabilities, Current Other accrued expenses Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Accumulated depreciation and amortization Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Accumulated Other Comp Income (Loss) [Member] Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Non-cash items included in net earnings: Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock compensation expense Allowance for Doubtful Accounts Receivable, Current Allowances for accounts receivable Amended complaint. Amended Complaint [Member] Amended Complaint [Member] Amendment Flag Amendment Flag Americas [Member] Americas [Member] Amortization of deferred instrument costs. Amortization Of Deferred Instrument Costs Amortization of deferred instrument costs Amortization of Intangible Assets Amortization of intangible assets Amount deductible from Insurance coverage. Amount deductible from Insurance coverage Amount deductible from insurance coverage Antidilutive securities excluded from Computation. Antidilutive Securities Excluded From Computation [Abstract] ANTI-DILUTIVE SECURITIES: Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common share options and restricted share units Assets Total assets TOTAL ASSETS Assets, Current Total current assets Assets, Current [Abstract] CURRENT ASSETS Amount of long-lived assets or a modification to long-lived assets under construction that include costs to date on capital projects that have not been completed and assets that are not ready to be placed into service. Assets Under Construction Construction in progress Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Blood chemistry assays. Blood chemistry assays [Member] Blood Chemistry Assays [Member] Buildings and Improvements, Gross Buildings and improvements Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Capitalized Contract Cost, Amortization Period Contract cost, amortization period Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents, at Carrying Value Cash and Equivalents Cash and cash equivalents Cash and equivalents Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents Disclosure [Text Block] Cash and Equivalents Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Cash, Cash Equivalents, and Short-term Investments [Abstract] Cash, Cash Equivalents, and Short-term Investments [Abstract] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and Equivalents and Restricted Cash at End of Period Cash and Equivalents and Restricted Cash at Beginning of Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net Increase (Decrease) in Cash and Equivalents and Restricted Cash Cash [Member] Cash [Member] Class action complaint one. Class Action Complaint One [Member] Class Action Complaint One [Member] Class action complaint two. Class Action Complaint Two [Member] Class Action Complaint Two [Member] Commitments and Contingencies COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Common Stock, Dividends, Per Share, Cash Paid Cash dividends per common share Common Stock, Dividends, Per Share, Declared DIVIDENDS DECLARED PER COMMON SHARE Common Stock [Member] Common Shares Issued [Member] Common Stock, No Par Value Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Value, Issued Common shares, no par value; 71,000,000 shares authorized, 42,488,602 and 42,399,962 shares issued, respectively Compensating Balance, Amount Cash compensating balance Comprehensive Income (Loss), Net of Tax, Attributable to Parent COMPREHENSIVE INCOME Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk, Percentage Concentration risk percentage Concentration Risk Type [Domain] Concentration Risk Type [Domain] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Contract Termination [Member] Lease and Other Contract Termination Fees [Member] Corporate, Non-Segment [Member] Corporate [Member] Cost of Goods and Services Sold COST OF SALES Counterparty Name [Axis] Counterparty Name [Axis] Cumulative Effect on Retained Earnings, Net of Tax Reduction to opening balance of retained earnings Current Fiscal Year End Date Current Fiscal Year End Date Customer Concentration Risk [Member] Customer Concentration Risk [Member] Customer lists and relationships, and supply agreements. Customer Lists And Relationships And Supply Agreements [Member] Customer Lists, Customer Relationships, and Supply Agreements [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Bank Credit Arrangements Debt Instrument [Line Items] Debt Instrument [Line Items] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Deferred Income Tax Expense (Benefit) Deferred income taxes Deferred instrument costs noncurrent. Deferred Instrument Costs Noncurrent Deferred instrument costs, net Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Deferred income taxes Deferred income taxes Depreciation Depreciation of property, plant and equipment Derivative Asset, Noncurrent Fair value of interest rate swap Interest rate swap asset Derivative, Notional Amount Notional balance Derivative, Swaption Interest Rate Bank credit arrangement, fixed interest rate percentage Diagnostics and life science restructuring. Diagnostics and Life Science Restructuring [Member] Diagnostics and Life Science Restructuring [Member] Diagnostics. Diagnostics [Member] Diagnostics [Member] DiaSorin Inc. DiaSorin Inc. [Member] DiaSorin Inc. [Member] Difference between Revenue Guidance in Effect before and after Topic 606 [Member] New Revenue Standard Adjustment [Member] Disaggregation of Revenue [Table Text Block] Summary of Disaggregation of Revenue Dividends, Common Stock, Cash Cash dividends paid Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type DOJ subpoena. Doj Subpoena [Member] DOJ Subpoena [Member] Earnings Per Share, Basic BASIC EARNINGS PER COMMON SHARE Earnings Per Share, Diluted DILUTED EARNINGS PER COMMON SHARE Effective income tax rate, estimate of temporary differences expected to be realized in next fiscal year, transitional blended rate. Effective Income Tax Rate, Estimate of Temporary Differences Expected to be Realized in Next Fiscal Year, Transitional Blended Rate Tax rate used for re-measurement of temporary differences expected to be realized during fiscal 2018 Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of Exchange Rate Changes on Cash and Equivalents and Restricted Cash EMEA [Member] EMEA [Member] Employee-related Liabilities, Current Accrued employee compensation costs Employee related liabilities noncurrent. Employee Related Liabilities Noncurrent Post-employment benefits Employee Severance [Member] Severance, Other Termination Benefits and Related Costs [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Emerging Growth Company Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Entity Small Business Entity Small Business Equity Component [Domain] Equity Component [Domain] Expected instrument utilization period. Expected Instrument Utilization Period Expected instrument utilization period Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets, Amortization Expense, after Year Five 2024 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Estimated amortization expense for intangible assets remainder of fiscal year 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2020 Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Gross Carrying Value Finite-Lived Intangible Assets, Gross [Abstract] Finite-Lived Intangible Assets, Gross [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Five Year Term Loan [Member] Five Year Term Loan [Member] Five - Year Term Loan [Member] Gastrointestinal assays. Gastrointestinal assays [Member] Gastrointestinal Assays [Member] General and Administrative Expense General and administrative Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Gross Profit GROSS PROFIT Immunoassays and blood chemistry assays. Immunoassays and blood chemistry assays [Member] Immunoassays & Blood Chemistry Assays [Member] Immunological reagents. Immunological reagents [Member] Immunological Reagents [Member] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest EARNINGS BEFORE INCOME TAXES Income Statement [Abstract] Income Statement [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income taxes disclosure. Income Taxes Disclosure [Line Items] Income Taxes Disclosure [Line Items] Income Taxes Disclosure [Table] Income Taxes Disclosure [Table] Income Taxes Disclosure [Table] Income Tax Expense (Benefit) INCOME TAX PROVISION Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Income Taxes Payable Income taxes payable Increase (Decrease) in Inventories Inventories Increase (Decrease) in Operating Capital [Abstract] Change in: Increase (Decrease) in Other Operating Assets and Liabilities, Net Other, net Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (decrease) in revenue, percentage. Increase (decrease) in revenue, percentage Revenue, % change Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Instruments [Member] Instruments [Member] Instruments [Member] Intangible Assets Disclosure [Text Block] Intangible Assets Intangible Assets, Net (Excluding Goodwill) Other intangible assets, net Interest Expense Interest expense A description of the terms of an interest rate swap. Interest Rate Swap Description Interest rate swap description Intersegment Eliminations [Member] Eliminations [Member] Intersegment Sales Intersegment Sales Net revenues Inventory, Current [Table] Inventory, Current [Table] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventories Inventory, Finished Goods, Net of Reserves Finished goods Inventory [Line Items] Inventory [Line Items] Inventory, Net Inventories Total Inventory, Raw Materials, Net of Reserves Raw materials Inventory, Work in Process, Net of Reserves Work-in-process Investment Income, Interest Interest income Kits and reagents. Kits And Reagents [Member] Kits and Reagents [Member] Land Land Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Lease elements. Lease Elements [Member] Lease Elements [Member] Legal Fees Litigation costs Legal Matters and Contingencies [Text Block] Litigation Matters Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] CURRENT LIABILITIES Liabilities, Noncurrent Total non-current liabilities Liabilities, Noncurrent [Abstract] NON-CURRENT LIABILITIES Life science. Life Science [Member] Life Science [Member] Long-term Line of Credit Borrowings outstanding under credit facility Line of Credit Facility, Expiration Date Expiration date of credit facility Line of Credit Facility, Maximum Borrowing Capacity Credit facility with a commercial bank Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Long-term Debt Term loan Long-term Debt, Current Maturities Current portion of long-term debt Long-term Debt, Maturities, Repayments of Principal in Year Three 2021 Long-term Debt, Maturities, Repayments of Principal in Year Two 2020 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2019 Long-term Debt, Excluding Current Maturities Long-term debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] EX-101.PRE 10 vivo-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2018	Jan. 31, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Trading Symbol	VIVO
Entity Registrant Name	MERIDIAN BIOSCIENCE INC
Entity Central Index Key	0000794172
Current Fiscal Year End Date	--09-30
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		42,489,202

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
NET REVENUES	$ 51,480	$ 52,283
COST OF SALES	19,908	20,273
GROSS PROFIT	31,572	32,010
OPERATING EXPENSES
Research and development	3,967	4,420
Selling and marketing	7,563	8,844
General and administrative	8,902	9,202
Restructuring costs		734
Litigation costs	589	749
Total operating expenses	21,021	23,949
OPERATING INCOME	10,551	8,061
OTHER INCOME (EXPENSE)
Interest income	149	72
Interest expense	(363)	(395)
Other, net	139	(80)
Total other expense	(75)	(403)
EARNINGS BEFORE INCOME TAXES	10,476	7,658
INCOME TAX PROVISION	2,370	1,356
NET EARNINGS	$ 8,106	$ 6,302
BASIC EARNINGS PER COMMON SHARE	$ 0.19	$ 0.15
DILUTED EARNINGS PER COMMON SHARE	$ 0.19	$ 0.15
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC	42,446	42,263
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARE UNITS	459	399
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-DILUTED	42,905	42,662
ANTI-DILUTIVE SECURITIES:
Common share options and restricted share units	684	1,034
DIVIDENDS DECLARED PER COMMON SHARE	$ 0.125	$ 0.125

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
NET EARNINGS	$ 8,106	$ 6,302
Other comprehensive income (loss):
Foreign currency translation adjustment	(716)	291
Unrealized gain (loss) on cash flow hedge	(577)	341
Income taxes related to items of other comprehensive income	145	(112)
Other comprehensive income (loss), net of tax	(1,148)	520
COMPREHENSIVE INCOME	$ 6,958	$ 6,822

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
NET EARNINGS	$ 8,106	$ 6,302
Non-cash items included in net earnings:
Depreciation of property, plant and equipment	1,253	1,146
Amortization of intangible assets	829	938
Amortization of deferred instrument costs		201
Stock-based compensation	1,670	1,759
Deferred income taxes	96	(1,624)
Change in:
Accounts receivable	317	(2,989)
Inventories	(37)	(2,353)
Prepaid expenses and other current assets	539	87
Accounts payable and accrued expenses	(4,081)	1,315
Income taxes payable	991	497
Other, net	(276)	(108)
Net cash provided by operating activities	9,407	5,171
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(1,109)	(1,234)
Net cash used for investing activities	(1,109)	(1,234)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid	(5,301)	(5,288)
Payments on term loan	(1,125)	(1,125)
Proceeds and tax benefits from exercises of stock options	145
Net cash used for financing activities	(6,281)	(6,413)
Effect of Exchange Rate Changes on Cash and Equivalents and Restricted Cash	(257)	115
Net Increase (Decrease) in Cash and Equivalents and Restricted Cash	1,760	(2,361)
Cash and Equivalents and Restricted Cash at Beginning of Period	60,763	58,072
Cash and Equivalents and Restricted Cash at End of Period	62,523	55,711
Cash and Equivalents	61,523	54,711
Restricted Cash	$ 1,000	$ 1,000

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018
CURRENT ASSETS
Cash and equivalents	$ 61,523	$ 59,763
Accounts receivable, less allowances of $331 and $310	31,791	32,336
Inventories	41,889	41,993
Prepaid expenses and other current assets	4,411	4,961
Total current assets	139,614	139,053
PROPERTY, PLANT AND EQUIPMENT, at Cost
Land	1,158	1,160
Buildings and improvements	32,443	32,444
Machinery, equipment and furniture	59,637	50,606
Construction in progress	1,727	1,631
Subtotal	94,965	85,841
Less: accumulated depreciation and amortization	64,108	55,846
Net property, plant and equipment	30,857	29,995
OTHER ASSETS
Goodwill	54,403	54,637
Other intangible assets, net	22,265	23,113
Restricted cash	1,000	1,000
Deferred instrument costs, net		1,239
Fair value of interest rate swap	1,145	1,722
Deferred income taxes	121	130
Other assets	452	488
Total other assets	79,386	82,329
TOTAL ASSETS	249,857	251,377
CURRENT LIABILITIES
Accounts payable	6,228	6,260
Accrued employee compensation costs	4,779	7,263
Other accrued expenses	3,035	5,065
Current portion of long-term debt	5,625	5,250
Income taxes payable	1,023	335
Total current liabilities	20,690	24,173
NON-CURRENT LIABILITIES
Post-employment benefits	2,490	2,646
Long-term debt	43,438	44,930
Long-term income taxes payable	736	441
Deferred income taxes	3,861	3,769
Total non-current liabilities	50,525	51,786
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Preferred stock, no par value; 1,000,000 shares authorized; none issued
Common shares, no par value; 71,000,000 shares authorized, 42,488,602 and 42,399,962 shares issued, respectively	0	0
Additional paid-in capital	130,876	129,193
Retained earnings	52,291	49,602
Accumulated other comprehensive loss	(4,525)	(3,377)
Total shareholders' equity	178,642	175,418
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 249,857	$ 251,377

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 331	$ 310
Preferred stock, par value
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value
Common stock, shares authorized	71,000,000	71,000,000
Common stock, shares issued	42,488,602	42,399,962

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Shareholders Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Shares Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comp Income (Loss) [Member]
Beginning balance at Sep. 30, 2017	$ 169,585		$ 125,608	$ 46,923	$ (2,946)
Beginning balance, Shares at Sep. 30, 2017		42,207
Cash dividends paid	(5,288)			(5,288)
Conversion of restricted share units	0	$ 0	0	0	0
Conversion of restricted share units, Shares		100
Stock compensation expense	1,759		1,759
NET EARNINGS	6,302			6,302
Foreign currency translation adjustment	291				291
Hedging activity, net of tax	229				229
Ending balance at Dec. 31, 2017	172,878		127,367	47,937	(2,426)
Ending balance, Shares at Dec. 31, 2017		42,307
Beginning balance at Sep. 30, 2018	175,418		129,193	49,602	(3,377)
Beginning balance, Shares at Sep. 30, 2018		42,400
Cash dividends paid	(5,301)			(5,301)
Conversion of restricted share units and exercise of stock options	13		13
Conversion of restricted share units and exercise of stock options, Shares		89
Stock compensation expense	1,670		1,670
NET EARNINGS	8,106			8,106
Foreign currency translation adjustment	(716)				(716)
Hedging activity, net of tax	(432)				(432)
Adoption of ASU 2014-09 \| Accounting Standards Update 2014-09 [Member]	(116)			(116)
Ending balance at Dec. 31, 2018	$ 178,642		$ 130,876	$ 52,291	$ (4,525)
Ending balance, Shares at Dec. 31, 2018		42,489

XML 18 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Shareholders Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Cash dividends per common share	$ 0.125	$ 0.125

XML 19 R9.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1.	Basis of Presentation

XML 20 R10.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

3 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Significant Accounting Policies

2.	Significant Accounting Policies

Revenue Recognition –

Adoption of New Standard

The following table summarizes the impact of the new revenue standard on our opening balance sheet:


	Balance at September 30, 2018			New Revenue Standard Adjustment			Balance at October 1, 2018
PROPERTY, PLAN AND EQUIPMENT
Machinery, equipment and furniture	$	50,606		$	8,696		$	59,302
Accumulated depreciation and amortization		(55,846	)		(7,611	)		(63,457	)
OTHER ASSETS
Deferred instrument costs, net		1,239			(1,239	)		—
NON-CURRENT LIABILITIES
Deferred income taxes		(3,769	)		38			(3,731	)
SHAREHOLDERS’ EQUITY
Retained earnings		(49,602	)		116			(49,486	)

Revenue Disaggregation

The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only):

Revenue by Reportable Segment & Geographic Region


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Americas	$	31,147	$	31,575		(1	)%
EMEA		5,085		5,415		(6	)%
ROW		433		500		(13	)%

Total Diagnostics		36,665		37,490		(2	)%

Life Science-
Americas		4,534		5,250		(14	)%
EMEA		7,455		5,185		44	%
ROW		2,826		4,358		(35	)%

Total Life Science		14,815		14,793		—	%

Consolidated	$	51,480	$	52,283		(2	)%

Revenue by Product Platform/Type


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Molecular assays	$	7,298	$	8,717		(16	)%
Immunoassays & blood chemistry assays		29,367		28,773		2	%

Total Diagnostics	$	36,665	$	37,490		(2	)%

Life Science-
Molecular reagents	$	6,589	$	5,688		16	%
Immunological reagents		8,226		9,105		(10	)%

Total Life Science	$	14,815	$	14,793		—	%

Revenue by Disease State (Diagnostics only)


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Gastrointestinal assays	$	18,633	$	20,270		(8	)%
Respiratory illness assays		7,977		7,486		7	%
Blood chemistry assays		4,466		4,266		5	%
Other		5,589		5,468		2	%

Total Diagnostics	$	36,665	$	37,490		(2	)%

Revenue Policies

Product Sales

Shipping and handling costs incurred after control of the product is transferred to our customers are treated as fulfillment costs and not a separate performance obligation.

Practical Expedients and Exemptions

Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

Reagent Rental Arrangements

For the portion of the transaction price allocated to the non-lease elements, which are principally the test kits, the related revenue will be recognized at a point-in-time when control transfers.

Recent Accounting Pronouncements –

Reclassifications –

XML 21 R11.htm IDEA: XBRL DOCUMENT

Cash and Equivalents

3 Months Ended

Dec. 31, 2018

Cash and Cash Equivalents [Abstract]

Cash and Equivalents

3.	Cash and Equivalents

Cash and equivalents include the following components:


	December 31, 2018				September 30, 2018
	Cash and Equivalents		Other Assets		Cash and Equivalents		Other Assets
Institutional money market funds	$	20,540	$	—	$	20,421	$	—
Cash on hand -
Restricted		—		1,000		—		1,000
Unrestricted		40,983		—		39,342		—

Total	$	61,523	$	1,000	$	59,763	$	1,000

XML 22 R12.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories

4.	Inventories

Inventories are comprised of the following:


	December 31, 2018		September 30, 2018
Raw materials	$	7,123	$	6,689
Work-in-process		12,037		12,098
Finished goods - instruments		1,224		1,191
Finished goods - kits and reagents		21,505		22,015

Total	$	41,889	$	41,993

XML 23 R13.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

5.	Intangible Assets

A summary of our acquired intangible assets subject to amortization, as of December 31, 2018 and September 30, 2018, is as follows:


	December 31, 2018				September 30, 2018
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	22,268	$	14,243	$	22,297	$	13,974
Trade names, licenses and patents		8,613		5,463		8,647		5,267
Customer lists, customer relationships and supply agreements		24,385		13,295		24,461		13,051
Non-compete agreements		720		720		720		720

Total	$	55,986	$	33,721	$	56,125	$	33,012

XML 24 R14.htm IDEA: XBRL DOCUMENT

Restructuring

3 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Restructuring

6.	Restructuring

A summary of the accrued liability associated with the restructuring costs as of December 31, 2018 and September 30, 2018, is as follows:


	December 31, 2018		September 30, 2018
Severance, other termination benefits and related costs	$	368	$	987
Lease and other contract termination fees		8		33
Other		5		6

Total	$	381	$	1,026

XML 25 R15.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

7.	Income Taxes

XML 26 R16.htm IDEA: XBRL DOCUMENT

Bank Credit Arrangements

3 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Bank Credit Arrangements

8.	Bank Credit Arrangements

XML 27 R17.htm IDEA: XBRL DOCUMENT

Reportable Segment and Major Customers Information

3 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Reportable Segment and Major Customers Information

9.	Reportable Segment and Major Customers Information

Segment information for the interim periods is as follows:


	Diagnostics		Life Science		Corporate⁽¹⁾			Eliminations⁽²⁾			Total
Three Months Ended December 31, 2018
Net revenues -
Third-Party	$	36,665	$	14,815	$	—		$	—		$	51,480
Inter-segment		163		176		—			(339	)		—
Operating income		8,786		5,129		(3,391	)		27			10,551
Goodwill (December 31, 2018)		35,213		19,190		—			—			54,403
Other intangible assets, net (December 31, 2018)		21,386		879		—			—			22,265
Total assets (December 31, 2018)		178,863		71,283		—			(289	)		249,857
Three Months Ended December 31, 2017
Net revenues -
Third-Party	$	37,490	$	14,793	$	—		$	—		$	52,283
Inter-segment		121		192		—			(313	)		—
Operating income		8,569		2,943		(3,555	)		104			8,061
Goodwill (September 30, 2018)		35,213		19,424		—			—			54,637
Other intangible assets, net (September 30, 2018)		22,068		1,045		—			—			23,113
Total assets (September 30, 2018)		180,978		70,341		—			58			251,377

(1)	Includes Restructuring and Litigation Costs of $589 and $1,483 in the quarters ended December 31, 2018 and 2017, respectively.

(2)	Eliminations consist of inter-segment transactions.

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Litigation Matters

3 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Litigation Matters

10.

Litigation Matters

XML 29 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Revenue Recognition

Revenue Recognition –

Adoption of New Standard

The following table summarizes the impact of the new revenue standard on our opening balance sheet:


	Balance at September 30, 2018			New Revenue Standard Adjustment			Balance at October 1, 2018
PROPERTY, PLAN AND EQUIPMENT
Machinery, equipment and furniture	$	50,606		$	8,696		$	59,302
Accumulated depreciation and amortization		(55,846	)		(7,611	)		(63,457	)
OTHER ASSETS
Deferred instrument costs, net		1,239			(1,239	)		—
NON-CURRENT LIABILITIES
Deferred income taxes		(3,769	)		38			(3,731	)
SHAREHOLDERS’ EQUITY
Retained earnings		(49,602	)		116			(49,486	)

Revenue Disaggregation

The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only):

Revenue by Reportable Segment & Geographic Region


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Americas	$	31,147	$	31,575		(1	)%
EMEA		5,085		5,415		(6	)%
ROW		433		500		(13	)%

Total Diagnostics		36,665		37,490		(2	)%

Life Science-
Americas		4,534		5,250		(14	)%
EMEA		7,455		5,185		44	%
ROW		2,826		4,358		(35	)%

Total Life Science		14,815		14,793		—	%

Consolidated	$	51,480	$	52,283		(2	)%

Revenue by Product Platform/Type


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Molecular assays	$	7,298	$	8,717		(16	)%
Immunoassays & blood chemistry assays		29,367		28,773		2	%

Total Diagnostics	$	36,665	$	37,490		(2	)%

Life Science-
Molecular reagents	$	6,589	$	5,688		16	%
Immunological reagents		8,226		9,105		(10	)%

Total Life Science	$	14,815	$	14,793		—	%

Revenue by Disease State (Diagnostics only)


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Gastrointestinal assays	$	18,633	$	20,270		(8	)%
Respiratory illness assays		7,977		7,486		7	%
Blood chemistry assays		4,466		4,266		5	%
Other		5,589		5,468		2	%

Total Diagnostics	$	36,665	$	37,490		(2	)%

Revenue Policies

Product Sales

Shipping and handling costs incurred after control of the product is transferred to our customers are treated as fulfillment costs and not a separate performance obligation.

Practical Expedients and Exemptions

Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

Reagent Rental Arrangements

For the portion of the transaction price allocated to the non-lease elements, which are principally the test kits, the related revenue will be recognized at a point-in-time when control transfers.

Recent Accounting Pronouncements

Recent Accounting Pronouncements –

Reclassifications

Reclassifications –

XML 30 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

3 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Impact of New Revenue Standard on Opening Balance Sheet

The following table summarizes the impact of the new revenue standard on our opening balance sheet:


	Balance at September 30, 2018			New Revenue Standard Adjustment			Balance at October 1, 2018
PROPERTY, PLAN AND EQUIPMENT
Machinery, equipment and furniture	$	50,606		$	8,696		$	59,302
Accumulated depreciation and amortization		(55,846	)		(7,611	)		(63,457	)
OTHER ASSETS
Deferred instrument costs, net		1,239			(1,239	)		—
NON-CURRENT LIABILITIES
Deferred income taxes		(3,769	)		38			(3,731	)
SHAREHOLDERS’ EQUITY
Retained earnings		(49,602	)		116			(49,486	)

Summary of Disaggregation of Revenue

The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only):

Revenue by Reportable Segment & Geographic Region


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Americas	$	31,147	$	31,575		(1	)%
EMEA		5,085		5,415		(6	)%
ROW		433		500		(13	)%

Total Diagnostics		36,665		37,490		(2	)%

Life Science-
Americas		4,534		5,250		(14	)%
EMEA		7,455		5,185		44	%
ROW		2,826		4,358		(35	)%

Total Life Science		14,815		14,793		—	%

Consolidated	$	51,480	$	52,283		(2	)%

Revenue by Product Platform/Type


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Molecular assays	$	7,298	$	8,717		(16	)%
Immunoassays & blood chemistry assays		29,367		28,773		2	%

Total Diagnostics	$	36,665	$	37,490		(2	)%

Life Science-
Molecular reagents	$	6,589	$	5,688		16	%
Immunological reagents		8,226		9,105		(10	)%

Total Life Science	$	14,815	$	14,793		—	%

Revenue by Disease State (Diagnostics only)


	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Gastrointestinal assays	$	18,633	$	20,270		(8	)%
Respiratory illness assays		7,977		7,486		7	%
Blood chemistry assays		4,466		4,266		5	%
Other		5,589		5,468		2	%

Total Diagnostics	$	36,665	$	37,490		(2	)%

XML 31 R21.htm IDEA: XBRL DOCUMENT

Cash and Equivalents (Tables)

3 Months Ended

Dec. 31, 2018

Cash and Cash Equivalents [Abstract]

Components of Cash and Cash Equivalents

Cash and equivalents include the following components:


	December 31, 2018				September 30, 2018
	Cash and Equivalents		Other Assets		Cash and Equivalents		Other Assets
Institutional money market funds	$	20,540	$	—	$	20,421	$	—
Cash on hand -
Restricted		—		1,000		—		1,000
Unrestricted		40,983		—		39,342		—

Total	$	61,523	$	1,000	$	59,763	$	1,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Components of Inventories

Inventories are comprised of the following:


	December 31, 2018		September 30, 2018
Raw materials	$	7,123	$	6,689
Work-in-process		12,037		12,098
Finished goods - instruments		1,224		1,191
Finished goods - kits and reagents		21,505		22,015

Total	$	41,889	$	41,993

XML 33 R23.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Acquired Intangible Assets Subject to Amortization

A summary of our acquired intangible assets subject to amortization, as of December 31, 2018 and September 30, 2018, is as follows:


	December 31, 2018				September 30, 2018
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	22,268	$	14,243	$	22,297	$	13,974
Trade names, licenses and patents		8,613		5,463		8,647		5,267
Customer lists, customer relationships and supply agreements		24,385		13,295		24,461		13,051
Non-compete agreements		720		720		720		720

Total	$	55,986	$	33,721	$	56,125	$	33,012

XML 34 R24.htm IDEA: XBRL DOCUMENT

Restructuring (Tables)

3 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Schedule of Accrued Liability Associated With Restructuring Costs

A summary of the accrued liability associated with the restructuring costs as of December 31, 2018 and September 30, 2018, is as follows:


	December 31, 2018		September 30, 2018
Severance, other termination benefits and related costs	$	368	$	987
Lease and other contract termination fees		8		33
Other		5		6

Total	$	381	$	1,026

XML 35 R25.htm IDEA: XBRL DOCUMENT

Reportable Segment and Major Customers Information (Tables)

3 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment Information

Segment information for the interim periods is as follows:


	Diagnostics		Life Science		Corporate⁽¹⁾			Eliminations⁽²⁾			Total
Three Months Ended December 31, 2018
Net revenues -
Third-Party	$	36,665	$	14,815	$	—		$	—		$	51,480
Inter-segment		163		176		—			(339	)		—
Operating income		8,786		5,129		(3,391	)		27			10,551
Goodwill (December 31, 2018)		35,213		19,190		—			—			54,403
Other intangible assets, net (December 31, 2018)		21,386		879		—			—			22,265
Total assets (December 31, 2018)		178,863		71,283		—			(289	)		249,857
Three Months Ended December 31, 2017
Net revenues -
Third-Party	$	37,490	$	14,793	$	—		$	—		$	52,283
Inter-segment		121		192		—			(313	)		—
Operating income		8,569		2,943		(3,555	)		104			8,061
Goodwill (September 30, 2018)		35,213		19,424		—			—			54,637
Other intangible assets, net (September 30, 2018)		22,068		1,045		—			—			23,113
Total assets (September 30, 2018)		180,978		70,341		—			58			251,377

(1)	Includes Restructuring and Litigation Costs of $589 and $1,483 in the quarters ended December 31, 2018 and 2017, respectively.

(2)	Eliminations consist of inter-segment transactions.

XML 36 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Oct. 01, 2018	Dec. 31, 2018	Sep. 30, 2018
Schedule Of Accounting Policies [Line Items]
Expected instrument utilization period			3 years
Revenue, description of payment terms		30 to 90 days from the date of shipment or satisfaction of the performance obligation
Maximum [Member]
Schedule Of Accounting Policies [Line Items]
Contract cost, amortization period		1 year
Maximum [Member] \| Reagent Rental Arrangements [Member] \| Lease Elements [Member] \| Product Concentration Risk [Member] \| Revenues [Member]
Schedule Of Accounting Policies [Line Items]
Concentration risk percentage		1.00%
Accounting Standards Update 2014-09 [Member]
Schedule Of Accounting Policies [Line Items]
Reduction to opening balance of retained earnings	$ (116)

XML 37 R27.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Summary of Impact of New Revenue Standard on Opening Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Oct. 01, 2018	Sep. 30, 2018
PROPERTY, PLAN AND EQUIPMENT
Machinery, equipment and furniture	$ 59,637	$ 59,302	$ 50,606
Accumulated depreciation and amortization	(64,108)	(63,457)	(55,846)
OTHER ASSETS
Deferred instrument costs, net			1,239
NON-CURRENT LIABILITIES
Deferred income taxes	(3,861)	(3,731)	(3,769)
SHAREHOLDERS' EQUITY
Retained earnings	$ (52,291)	(49,486)	$ (49,602)
New Revenue Standard Adjustment [Member] \| Accounting Standards Update 2014-09 [Member]
PROPERTY, PLAN AND EQUIPMENT
Machinery, equipment and furniture		8,696
Accumulated depreciation and amortization		(7,611)
OTHER ASSETS
Deferred instrument costs, net		(1,239)
NON-CURRENT LIABILITIES
Deferred income taxes		(38)
SHAREHOLDERS' EQUITY
Retained earnings		$ 116

XML 38 R28.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Summary of Disaggregation of Revenue by Reportable Segment and Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 51,480	$ 52,283
Revenue, % change	(2.00%)
Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 36,665	37,490
Revenue, % change	(2.00%)
Diagnostics [Member] \| Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 31,147	31,575
Revenue, % change	(1.00%)
Diagnostics [Member] \| EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 5,085	5,415
Revenue, % change	(6.00%)
Diagnostics [Member] \| ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 433	500
Revenue, % change	(13.00%)
Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 14,815	14,793
Life Science [Member] \| Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 4,534	5,250
Revenue, % change	(14.00%)
Life Science [Member] \| EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 7,455	5,185
Revenue, % change	44.00%
Life Science [Member] \| ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 2,826	$ 4,358
Revenue, % change	(35.00%)

XML 39 R29.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 51,480	$ 52,283
Revenue, % change	(2.00%)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 36,665	37,490
Revenue, % change	(2.00%)
Diagnostics [Member] \| Molecular Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 7,298	8,717
Revenue, % change	(16.00%)
Diagnostics [Member] \| Immunoassays & Blood Chemistry Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 29,367	28,773
Revenue, % change	2.00%
Life Science [Member]
Segment Reporting Information [Line Items]
Revenue	$ 14,815	14,793
Life Science [Member] \| Molecular Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 6,589	5,688
Revenue, % change	16.00%
Life Science [Member] \| Immunological Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 8,226	$ 9,105
Revenue, % change	(10.00%)

XML 40 R30.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Summary of Disaggregation of Revenue by Disease State (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 51,480	$ 52,283
Revenue, % change	(2.00%)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 36,665	37,490
Revenue, % change	(2.00%)
Diagnostics [Member] \| Gastrointestinal Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 18,633	20,270
Revenue, % change	(8.00%)
Diagnostics [Member] \| Respiratory Illness Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 7,977	7,486
Revenue, % change	7.00%
Diagnostics [Member] \| Blood Chemistry Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 4,466	4,266
Revenue, % change	5.00%
Diagnostics [Member] \| Other [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,589	$ 5,468
Revenue, % change	2.00%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 61,523	$ 59,763	$ 54,711
Other assets	1,000	1,000
Institutional Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	20,540	20,421
Other Restricted Cash [Member]
Cash and Cash Equivalents [Line Items]
Other assets	1,000	1,000
Cash [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 40,983	$ 39,342

XML 42 R32.htm IDEA: XBRL DOCUMENT

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018
Inventory [Line Items]
Raw materials	$ 7,123	$ 6,689
Work-in-process	12,037	12,098
Total	41,889	41,993
Instruments [Member]
Inventory [Line Items]
Finished goods	1,224	1,191
Kits and Reagents [Member]
Inventory [Line Items]
Finished goods	$ 21,505	$ 22,015

XML 43 R33.htm IDEA: XBRL DOCUMENT

Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 55,986	$ 56,125
Accumulated Amortization	33,721	33,012
Manufacturing Technologies, Core Products and Cell Lines [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	22,268	22,297
Accumulated Amortization	14,243	13,974
Trade Names, Licenses and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	8,613	8,647
Accumulated Amortization	5,463	5,267
Customer Lists, Customer Relationships, and Supply Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	24,385	24,461
Accumulated Amortization	13,295	13,051
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	720	720
Accumulated Amortization	$ 720	$ 720

XML 44 R34.htm IDEA: XBRL DOCUMENT

Intangible Assets- Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 829	$ 938
Estimated amortization expense for intangible assets remainder of fiscal year 2019	2,487
2020	3,156
2021	2,560
2022	2,182
2023	2,170
2024	$ 2,166

XML 45 R35.htm IDEA: XBRL DOCUMENT

Restructuring - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 734
Diagnostics and Life Science Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs		$ 6,332

XML 46 R36.htm IDEA: XBRL DOCUMENT

Restructuring - Schedule of Accrued Liability Associated With Restructuring Costs (Detail) - Diagnostics and Life Science Restructuring [Member] - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Accrued liability associated with the restructuring costs	$ 381	$ 1,026
Severance, Other Termination Benefits and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Accrued liability associated with the restructuring costs	368	987
Lease and Other Contract Termination Fees [Member]
Restructuring Cost and Reserve [Line Items]
Accrued liability associated with the restructuring costs	8	33
Other [Member]
Restructuring Cost and Reserve [Line Items]
Accrued liability associated with the restructuring costs	$ 5	$ 6

XML 47 R37.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes Disclosure [Line Items]
Provisional repatriation transition tax	$ 876	$ 854
Tax rate used for re-measurement of temporary differences expected to be realized during fiscal 2018		24.50%
Tax rate used for re-measurement of remaining temporary differences	21.00%
Tax benefit from tax reform act		$ 1,695
Accrued Income Taxes Current [Member]
Income Taxes Disclosure [Line Items]
Provisional repatriation transition tax	$ 140
Accrued Income Taxes Noncurrent [Member]
Income Taxes Disclosure [Line Items]
Provisional repatriation transition tax	$ 736

XML 48 R38.htm IDEA: XBRL DOCUMENT

Bank Credit Arrangements - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Mar. 22, 2016
Debt Instrument [Line Items]
Notional balance	$ 60,000,000
Interest rate swap description	(i) notional reduction amounts and dates; (ii) LIBOR settlement rates; (iii) rate reset dates; and (iv) term/maturity.
Interest rate swap asset	$ 1,145,000	$ 1,722,000
Bank credit arrangement, fixed interest rate percentage	2.76%
Credit facility with a commercial bank	$ 30,000,000
Expiration date of credit facility	Mar. 31, 2021
Borrowings outstanding under credit facility	$ 0	$ 0
Cash compensating balance	1,000,000
Magellan [Member]
Debt Instrument [Line Items]
2019	4,125,000
2020	6,000,000
2021	$ 39,000,000
Five - Year Term Loan [Member] \| Magellan [Member]
Debt Instrument [Line Items]
Term loan			$ 60,000,000

XML 49 R39.htm IDEA: XBRL DOCUMENT

Reportable Segment and Major Customers Information - Additional Information (Detail) - Customer Concentration Risk [Member] - Customer	3 Months Ended		12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018
Two Diagnostic Manufacturing Customers [Member] \| Segment, Third-Party Sales Revenue [Member] \| Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of major customers	2	2
Concentration risk percentage	28.00%	15.00%
Two Diagnostic Distributor Customers [Member] \| Segment, Third-Party Sales Revenue [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of major customers	2	2
Two Diagnostic Distributor Customers [Member] \| Segment, Third-Party Sales Revenue [Member] \| Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	34.00%	32.00%
Two Diagnostic Distributor Customers [Member] \| Consolidated Accounts Receivable [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of major customers	2		2
Concentration risk percentage	14.00%		12.00%
Two Diagnostic Distributor Customers [Member] \| Revenues [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	24.00%	23.00%

XML 50 R40.htm IDEA: XBRL DOCUMENT

Reportable Segment and Major Customers Information - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018
Segment Reporting Information [Line Items]
NET REVENUES	$ 51,480	$ 52,283
Operating income	10,551	8,061
Goodwill	54,403		$ 54,637
Other intangible assets, net	22,265		23,113
Total assets	249,857		251,377
Operating Segments [Member] \| Diagnostics [Member]
Segment Reporting Information [Line Items]
NET REVENUES	36,665	37,490
Operating income	8,786	8,569
Goodwill	35,213		35,213
Other intangible assets, net	21,386		22,068
Total assets	178,863		180,978
Net revenues	163	121
Operating Segments [Member] \| Life Science [Member]
Segment Reporting Information [Line Items]
NET REVENUES	14,815	14,793
Operating income	5,129	2,943
Goodwill	19,190		19,424
Other intangible assets, net	879		1,045
Total assets	71,283		70,341
Net revenues	176	192
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income	(3,391)	(3,555)
Eliminations [Member]
Segment Reporting Information [Line Items]
Operating income	27	104
Total assets	(289)		$ 58
Net revenues	$ (339)	$ (313)

XML 51 R41.htm IDEA: XBRL DOCUMENT

Reportable Segment and Major Customers Information - Segment Information (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Corporate [Member]
Segment Reporting Information [Line Items]
Restructuring and litigation costs	$ 589	$ 1,483

XML 52 R42.htm IDEA: XBRL DOCUMENT

Litigation Matters - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Loss Contingencies [Line Items]
Amount deductible from insurance coverage	$ 500,000
Litigation costs	$ 589,000	$ 749,000
Class Action Complaint One [Member]
Loss Contingencies [Line Items]
Litigation filing date	Nov. 15, 2017
Provision for litigation losses	$ 0	0
Amended Complaint [Member]
Loss Contingencies [Line Items]
Litigation filing date	Apr. 16, 2018
Class Action Complaint Two [Member]
Loss Contingencies [Line Items]
Litigation filing date	Dec. 06, 2017
Provision for litigation losses	$ 0	0
DOJ Subpoena [Member]
Loss Contingencies [Line Items]
Litigation filing date	Apr. 17, 2018
Litigation costs	$ 540,000	0
DiaSorin Inc. [Member]
Loss Contingencies [Line Items]
Litigation costs	$ 50,000	$ 730,000

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 135 183 1 false 54 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.meridianbioscience.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfIncome Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfOtherComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 108 - Statement - Condensed Consolidated Statements of Changes in Shareholders Equity (Unaudited) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Condensed Consolidated Statements of Changes in Shareholders Equity (Unaudited) Statements 7 false false R8.htm 109 - Statement - Condensed Consolidated Statements of Changes in Shareholders Equity (Unaudited) (Parenthetical) Sheet http://www.meridianbioscience.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical Condensed Consolidated Statements of Changes in Shareholders Equity (Unaudited) (Parenthetical) Statements 8 false false R9.htm 110 - Disclosure - Basis of Presentation Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation Notes 9 false false R10.htm 111 - Disclosure - Significant Accounting Policies Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Significant Accounting Policies Notes 10 false false R11.htm 112 - Disclosure - Cash and Equivalents Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock Cash and Equivalents Notes 11 false false R12.htm 113 - Disclosure - Inventories Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories Notes 12 false false R13.htm 114 - Disclosure - Intangible Assets Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets Notes 13 false false R14.htm 115 - Disclosure - Restructuring Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock Restructuring Notes 14 false false R15.htm 116 - Disclosure - Income Taxes Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 15 false false R16.htm 117 - Disclosure - Bank Credit Arrangements Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Bank Credit Arrangements Notes 16 false false R17.htm 118 - Disclosure - Reportable Segment and Major Customers Information Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Reportable Segment and Major Customers Information Notes 17 false false R18.htm 119 - Disclosure - Litigation Matters Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock Litigation Matters Notes 18 false false R19.htm 120 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Significant Accounting Policies (Policies) Policies http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 19 false false R20.htm 121 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Significant Accounting Policies (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 20 false false R21.htm 122 - Disclosure - Cash and Equivalents (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlockTables Cash and Equivalents (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsCashAndCashEquivalentsDisclosureTextBlock 21 false false R22.htm 123 - Disclosure - Inventories (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventories (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Intangible Assets (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables Intangible Assets (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Restructuring (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables Restructuring (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Reportable Segment and Major Customers Information (Tables) Sheet http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Reportable Segment and Major Customers Information (Tables) Tables http://www.meridianbioscience.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 25 false false R26.htm 127 - Disclosure - Significant Accounting Policies - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation Significant Accounting Policies - Additional Information (Detail) Details 26 false false R27.htm 128 - Disclosure - Significant Accounting Policies - Summary of Impact of New Revenue Standard on Opening Balance Sheet (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfImpactOfNewRevenueStandardOnOpeningBalanceSheet Significant Accounting Policies - Summary of Impact of New Revenue Standard on Opening Balance Sheet (Detail) Details 27 false false R28.htm 129 - Disclosure - Significant Accounting Policies - Summary of Disaggregation of Revenue by Reportable Segment and Geographic Region (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueByReportableSegmentAndGeographicRegion Significant Accounting Policies - Summary of Disaggregation of Revenue by Reportable Segment and Geographic Region (Detail) Details 28 false false R29.htm 130 - Disclosure - Significant Accounting Policies - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueByProductPlatformType Significant Accounting Policies - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) Details 29 false false R30.htm 131 - Disclosure - Significant Accounting Policies - Summary of Disaggregation of Revenue by Disease State (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfDisaggregationOfRevenueByDiseaseState Significant Accounting Policies - Summary of Disaggregation of Revenue by Disease State (Detail) Details 30 false false R31.htm 132 - Disclosure - Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureCashAndEquivalentsComponentsOfCashAndCashEquivalents Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) Details 31 false false R32.htm 133 - Disclosure - Inventories - Components of Inventories (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureInventoriesComponentsOfInventories Inventories - Components of Inventories (Detail) Details 32 false false R33.htm 134 - Disclosure - Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureIntangibleAssetsSummaryOfAcquiredIntangibleAssetsSubjectToAmortization Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) Details 33 false false R34.htm 135 - Disclosure - Intangible Assets- Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation Intangible Assets- Additional Information (Detail) Details 34 false false R35.htm 136 - Disclosure - Restructuring - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureRestructuringAdditionalInformation Restructuring - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Restructuring - Schedule of Accrued Liability Associated With Restructuring Costs (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureRestructuringScheduleOfAccruedLiabilityAssociatedWithRestructuringCosts Restructuring - Schedule of Accrued Liability Associated With Restructuring Costs (Detail) Details 36 false false R37.htm 138 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 37 false false R38.htm 139 - Disclosure - Bank Credit Arrangements - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureBankCreditArrangementsAdditionalInformation Bank Credit Arrangements - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Reportable Segment and Major Customers Information - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureReportableSegmentAndMajorCustomersInformationAdditionalInformation Reportable Segment and Major Customers Information - Additional Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Reportable Segment and Major Customers Information - Segment Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureReportableSegmentAndMajorCustomersInformationSegmentInformation Reportable Segment and Major Customers Information - Segment Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Reportable Segment and Major Customers Information - Segment Information (Parenthetical) (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureReportableSegmentAndMajorCustomersInformationSegmentInformationParenthetical Reportable Segment and Major Customers Information - Segment Information (Parenthetical) (Detail) Details 41 false false R42.htm 143 - Disclosure - Litigation Matters - Additional Information (Detail) Sheet http://www.meridianbioscience.com/taxonomy/role/DisclosureLitigationMattersAdditionalInformation Litigation Matters - Additional Information (Detail) Details 42 false false All Reports Book All Reports vivo-20181231.xml vivo-20181231.xsd vivo-20181231_cal.xml vivo-20181231_def.xml vivo-20181231_lab.xml vivo-20181231_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 59 0001193125-19-034030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-034030-xbrl.zip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�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�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